**Protease allergens as initiators-regulators of allergic inflammation**

**Wai Tuck Soh1\*, Jihui Zhang2\*, Morley D Hollenberg3, Harissios Vliagoftis4, Marc E Rothenberg5, Caroline L Sokol6, Clive Robinson7, Alain Jacquet8.**

\*: co-first authors on this work

1. Max-Planck-Institute for Multidisciplinary Sciences, Göttingen, Germany.
2. State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of China.
3. Department of Physiology & Pharmacology and Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
4. Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine & Dentistry, and Alberta Respiratory Centre, University of Alberta, Edmonton, Alberta, Canada
5. Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
6. Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
7. Institute for Infection and Immunity, St George's University of London, London, UK
8. Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Author for correspondence: Assoc. Prof. Dr. Alain Jacquet

Department of Biochemistry, Faculty of Medicine,

Chulalongkorn University,

1873 Rama IV Road, Pathumwan,

Bangkok 10330, Thailand.

Tel: (+66) 02 2563659

Fax: (+66) 02 6523100

[alain.j@chula.ac.th](mailto:alain.j@chula.ac.th)

ORCID ID: 0000-0002-0980-9741

**5290 words**

**Short Title:** Innate Sensing of Protease Allergens

**Keywords:** Protease allergen; Epithelial Cell, Sensory Neuron, IL-33, Protease-activated receptor

**Abbreviations**

**ADAM A disintegrin and metalloprotease**

**ADI Allergen delivery inhibitor**

**AEC Airway epithelial cell**

**ATP Adenosine 5’-triphosphate**

**CCL C-C chemokine ligand**

**CXCL C-X-C chemokine ligand**

**CD Cluster of differentiation**

**cDC2 Myeloid/conventional dendritic cell**

**DAMP Danger-associated molecular pattern**

**DC Dendritic cell**

**DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin**

**EGFR Epidermal growth factor receptor**

**GM-CSF Granulocyte macrophage-colony stimulating factor**

**GPCR G protein-coupled receptor**

**HDM House dust mite**

**IDO Indoleamine 2,3-dioxygenase**

**IL Interleukin**

**ILC2 Type 2 innate lymphoid cell**

**MD2 Myeloid differentiation factor 2**

**MDA-5 Melanoma differentiation-associated protein-5**

**MRGPR Mas-related G-protein-coupled receptors**

**PAR Protease-activated receptor**

**PRR Pattern-recognition receptor**

**RIG-I Retinoic acid inducible gene-I**

**RiPIL-33 Ripoptosome IL-33 maturation**

**SPINK Serine peptidase inhibitor, kazal type**

**TH2 Type 2 T-helper cell**

**TH17 Type 17 T-helper cell**

**TJ Tight junction**

**TLR Toll-like receptor**

**TRPV Transient receptor potential vanilloid-type**

**TSLP Thymic stromal lymphopoietin**

**ZO-1 Zonula occludens-1**

**Abstract**

Tremendous progress in the last few years has been made to explain how seemingly harmless environmental proteins from different origins can induce potent Th2-biased inflammatory responses. Convergent findings have shown the key roles of allergens displaying proteolytic activity in the initiation and progression of the allergic response. **Through their propensity to activate IgE-independent inflammatory pathways,** ~~Certain~~ **certain** allergenic proteases are now considered as initiators for sensitization ~~by~~ **to** themselves and ~~by~~ **to** non-protease allergens,~~through their propensity to activate IgE-independent inflammatory pathways~~. The protease allergens degrade junctional proteins of keratinocytes or airways epithelium to facilitate allergen delivery across the epithelial barrier and their subsequent uptake by antigen-presenting cells. Epithelial injuries mediated by these proteases together with their sensing by protease-activated receptors (PARs) elicit potent inflammatory responses resulting in the release of pro-Th2 cytokines (IL-6, IL-25, IL-1β, TSLP) and danger-associated molecular patterns (DAMPs; IL-33, ATP, **uric acid**). Recently, protease allergens were shown to cleave the protease sensor domain of IL-33 to produce a super-active form of the alarmin. At the same time, proteolytic cleavage of fibrinogen can trigger TLR4 signaling, and cleavage of various cell surface receptors further shape the Th2 polarization. Remarkably, the sensing of protease allergens by nociceptive neurons can represent a primary step in the development of the allergic response. The goal of this review is to highlight the multiple innate immune mechanisms triggered by protease allergens that converge to initiate the allergic response.

**Introduction**

Allergic inflammation was once simply described by the cross-linking of allergen-specific IgE and activation of CD4+ T cells to produce Th2 cytokines (eg IL-4, IL-5 or IL-13), is now known to be dominated by more complex and nuanced interactions between the immune cells and barrier tissues. Recent insights have exposed key roles for skin, airway (nasal, bronchial) and gastrointestinal (esophageal and intestinal) epithelial cells, as well as sensory neurons in allergen sensing.1 These observations have underlined the role of allergen bioactivity and function in the initiation and propagation of an allergic immune response. However, our knowledge of the intrinsic proinflammatory properties of allergens remains limited. One functional attribute of allergens known to determine their allergenicity is proteolytic activity**. Proteolytic allergens are found in major airborne sensitizers, but are a restricted feature in the entirety of the known allergome.2 Despite their uncommonness**, the isolation and characterization of IgE binding capacity of all the proteolytic enzymes (termed proteases or proteinases) from allergenic sources **remains an incomplete and challenging task.**

A distinguishing feature of protease allergens is their intrinsic ability to overcome host tolerance. Without additional adjuvants, allergenic house dust mite (HDM) extracts, papain or fungal allergens induce allergen-specific IgE, initiate gene expression and mediator release, and recruit eosinophils and antigen presenting cells to challenged airways or skin.3-6 However, this process is prevented by **specific6,7 and non-specific** protease inhibitors6-12, or inhibitors of signaling pathways activated by protease allergens.13-18 Furthermore, the addition of a protease to an enzymatically inactive protein can render that protein allergenic.4,10,19-21 Thus, not only does protease activity endow an allergen with its adjuvant activity, but it also acts as an exogenous allergic adjuvant for other inert or otherwise not allergenic proteins. For those reasons, protease allergens could be defined as initiator allergens promoting allergy development

The broad substrate specificity of protease allergens means that a clear identification of their immune biosensors is a challenging task. HDM proteases and papain can directly activate mast cells and basophils. However, while mast cell function may promote sensitization, neither mast cells nor basophils are necessary for the allergic sensitization.8,22-24 That said, mild eosinophilia following protease delivery to the airways of HDM-naïve wild type or Rag-2 deficient mice indicates the presence of IgE-independent sensing mechanisms for protease allergens.6,8,25,26 Despite these complexities, fundamental advances have been made in understanding allergic immune sensitization by protease allergens to clarify the process of protease allergen sensing. The purpose of this review is to characterize the different molecular mechanisms triggered by protease allergens which promote the development of allergic diseases (Box 1). Particular attention is given to the effects of protease allergens on epithelial cells and sensory neurons.

**BOX 1 Major milestone discoveries**

* **The protease activity of allergens is sufficient to elicit Pro-Th2 innate immune signaling pathways**
* **Protease allergens can alter epithelial integrity, permitting their entry where they can maintain activity by altering anti-protease defenses.**
* **Cleavage of fibrinogen by protease allergens or by thrombin matured by protease allergens elicits allergic responses through Toll-like receptor-4 (TLR4) activation**
* **Serine protease allergens trigger protease-activated receptor 2 (PAR2) activation**
* **Protease allergens induce the release of the alarmin IL-33, as well as cleavage to its highly active state, although this response is not limited to protease allergens**
* **Protease allergens directly activate nociceptive neurons, enriched in Transient receptor potential vanilloid-type 1 (TRPV1)+ neurons, which promote the migration of Th2-skewing dendritic cells**

**Main protease allergens**

**In December 2022**, the updated list of allergens from the WHO IUIS Allergen database (Official List of Allergens issued by the International Union of Immunological Societies Allergen Nomenclature Sub-committee) (<http://www.allergen.org>) included **1089 entries**. Of these, **only** 57 were classified as proteases or peptidases based on their protein sequence/structural similarities with archetypal serine, cysteine, aspartic or metallo-proteases (Table S1). A limited number of allergenic sources contain protease allergens: house dust mites (HDM), cockroaches, fungi, pollens, fruits, and bee venoms. However, as only few allergens have yet been characterized for their proteolytic activity and propensity to stimulate innate immune signaling pathways, the present review will be focused mainly on the protease allergens listed in Table 1. These endopeptidases display cysteine or serine protease activity, according to their active site residues respectively, Cysteine-Histidine-Asparagine or Serine-Histidine-Aspartic acid (Fig.1). Although the physiological roles of these proteases in their corresponding allergenic source remain to be elucidated, it is reasonable to assume their involvement in protein turnover, nutrient production through proteinaceous substrate digestion (in the digestive gut for HDM and cockroach or externally for fungi), fungal/plant defense system and also immune evasion.27-29 Nearly all proteases are produced as enzymatically inactive zymogens and require spatiotemporal activation either by auto-catalytic processing or activation by other proteases. A typical example is the natural self-maturation of the HDM allergen Der p 1 under acidic conditions30. This process also plays a key role in the maturation of serine protease allergens Der p 3, Der p 6 and Der p 9.31

Protease allergens are usually stable and abundant proteins in their allergenic sources (up to several hundreds of µg/g of extracts for the highly expressed ones).11,32 Their presence in mite fecal pellets, cockroach frasses or their extensive secretion by fungi can greatly facilitate their airborne transmission. Collectively, these properties could explain, at least in part, why the identified protease allergens are major sensitizers, with IgE binding frequencies higher than 50% ([www.allergen.org](http://www.allergen.org)).

**Protease Allergens and Tissue Barrier Permeability**

In the airway, skin, and esophageal epithelium, tight junctions (TJs) have an important role in forming the dynamic protective barriers at these surfaces.33 Disruption of these barriers perturbs tissue homeostasis and enables external agents such as allergens to gain increased contact with the immune system and sensory neurons.5,24

The principal adhesion proteins of TJs are the claudin family, MARVEL domain proteins such as occludin, and junction-associated molecules (JAMs). TJs are theoretically capable of permitting passage to some low molecular weight allergens (Stokes’ radius <2 nm). In reality, the transepithelial flow of the ~14 kDa group 2 HDM allergens is low unless catalytically competent group 1 allergens are also present, indicating that shape, oligomerisation and desolvation are additional influencers of allergen permeation, and underscoring the importance of protease allergens in accelerating the flux of unrelated allergens through direct and indirect means.7

HDM fecal pellets and HDM allergen extracts both trigger the cleavage of TJs in bronchial epithelial cells with a concomitant rise in barrier permeability,6,34 facilitating the sensing of allergens by dendritic cells and sensory neurons (Fig. 2). These effects are replicated by Der p 1 or the serine peptidase HDM allergens.6 Predictably, the actions of Der p 1 are prevented by Der p 1-selective inhibitors, but these agents also substantially inhibit the effects of HDM allergen extracts suggesting that group 1 allergens spearhead the proteolytic attack.6

Disruption of junctional proteins was also observed in airway epithelial cells (AECs) treated with the fungal (Pen c 13) or the cockroach (Per a 10) serine protease allergen.37,38 Similar barrier erosion occurs in primary cultures of human sinonasal cells exposed to Der p 1 39 or serine protease activity of *Alternaria* extracts,40 in the skin of mice exposed to Der f 1,41 keratinocyte models and mouse skin exposed to papain.10,42,43. Occludin and claudins are target substrates of HDM protease allergens and specific cleavage sites have been identified in extracellular domains. Notably, occludin and claudin proteins (*e.g.,* -1, -3, -4, -5, -7 and -18) which regulate paracellular permeability conserve a Leu-Leu dyad cleavage ‘hotspot’ for group 1 HDM allergens.7,26 For mites, junctional complexes in the airway epithelium also undergo indirect proteolysis which may be PAR-dependent.6,7,15,34 A recent study showed that the fungal allergen Asp f 13 damaged airway epithelial TJ and E-Cadherin (**adherens junction**). In bronchiolar club cells, a distinct subset of epithelial cells,44 this junction injury triggered a calcium influx sensed by the mechanosensor TRPV4 leading to allergic inflammation. In addition to airways and skin, other barriers may be affected by protease allergens (Fig. 2). Although conventionally considered as being encountered via the airways, Der p 1 was detected in human gut and HDM extracts were shown to augment colonic barrier permeability in a cysteine protease-dependent manner.45 Moreover, HDM extracts can degrade occludin and ZO-1 in the human intestinal epithelial Caco-2 cell line. Collectively, these findings suggest the possibility of oral sensitization to HDM allergens through protease-dependent events.45 Analogously, kiwi fruit actinidin (Act d 1) increases intestinal permeability in tandem with the expression of the Th2-promoting cytokines IL-25, IL-33 and TSLP *in vivo*46 and cleavage of occludin and ZO-1 has been observed in Act d 1-treated intestinal epithelial cells.47,48

Protease allergen effects on TJs are highly localized, temporary and can be fully reversible. However, these permeability changes, for a time, allow any allergen an increased probability of contact with antigen presenting cells and sensory neurons. This process may be aggravated in human disorders where the homeostatic anti-protease systems, normally found in barrier tissues, are lost. In the skin and esophagus, epithelial differentiation is accompanied by expression of high levels of serine protease inhibitors such as SPINK5 or SPINK7 (serine peptidase inhibitor, kazal type 5 and 7, respectively).49 Genetic or acquired lost expression of these protease inhibitors results in uncontrolled serine protease activity involving kallikrein family members which trigger PAR2 and subsequent transcriptional activation of the *TSLP* gene and subsequent type 2 immune responses.50-52 The contribution of endogenous versus exogenous proteases in this type 2 inflammation remains to be determined.

Pollen extracts or fresh pollen from various sources (*e.g., Ambrosia trifida, Poa pratensis, Betula verrucosa, Lilium logifolium, Chenopodium album, Plantago lanceolata, Eucalytus globulus, Olea europaea, Dactylis glomerulosa, Cupressa sempervirens, Pinus sylvestris*) cleave TJs by disrupting claudin-1, occludin, ZO-1 and the adherens junction protein E-cadherin in a manner reminiscent of HDM protease allergens, increasing permeability in AECs. Cysteine, serine and metalloprotease activity has been presumptively linked to these effects.53-55 Of note, IgE-reactive cysteine proteases have been reported in the coat of *Cynodon dactylon, Sorghum halepense,* and *Phleum pratense* pollen*.*56Although the effects of these pollen coat cysteine proteases on TJs were not elucidated, the coat cysteine protease from *Bermuda Grass* pollen increased permeability and cell detachment of human airway epithelial cells.To date, it must be pointed out that only the cysteine protease Amb a 11 has been recognized as an allergen.57 Recently, a IgE-reactive cysteine protease allergen displaying 95% sequence identity with Am b 11 was isolated from *A. trifida*.58 Moreover, a potential Der p 1 homologue has been reported in *Betula verrucosa* and *Pinus sylvestris.*59

**Activation of structural and immune cells by protease allergens**

Although degradomic methodologies have not been fully applied to protease allergens, several protein substrates targeted by allergenic proteases have been identified (Fig. 2). Common amongst these targets is linkage to mechanisms promoting **and/or regulating** Th2 immune responses6,26,60 or skewing to Th17 responses.5,18 **The activation of PAR2 by protease allergens is separately described in the next section.**

HDM allergens Der p 1 and Der f 1 **can** degrade airway surfactant protein-A and -D (part of the soluble innate immune system collectin) **predisposing** to compromised epithelial barrier ~~integrity~~**defences**.61 In addition, Der p 1 also degraded **α1-antitrypsin, secretory leukocyte protease inhibitor and elafin which are** ~~some protease inhibitors from the~~ **components of the** lung antiprotease network~~such as elastase inhibitors (alpha1-antitrypsin, secretory leukocyte protease inhibitor and elafin)~~.**62 Der p 1 instigates the canonical, thrombin-dependent activation of PAR1 and PAR4 in AECs by its capacity to mature prothrombin into thrombin.74-76 The proteolysis of fibrinogen by thrombin releases fibrinogen cleavage products that activate Toll-like receptor (TLR4) (with clot formation)77 (Fig.2). Fungal protease allergens as well as HDM extracts can selectively promote the fibrinogen cleavage product-TLR4 axis.78 Thrombin was recently shown to activate the maturation of interleukin-1α (IL-1α), a central pleiotropic pro-inflammatory cytokine.79 In addition, this mechanism entrains other signaling pathways (epidermal growth factor receptor (EGFR) signaling, activation of myosin motors, gating of pannexons, ATP release, ligation of P2Y2 and P2X7 purinoceptors, activation of a disintegrin and metalloprotease 10 (ADAM10), ligation of TLR4, intracellular ROS generation) leading to IgE-independent cytokine production (Fig.3). Of note, the *Aspergillus* proteases-mediated proinflammatory responses in primary bronchial epithelial cells was dependent on the mitochondrial ROS production.**

**Der p 1-induced ADAM10 activation mediates E-Cadherin shedding for the untethering of ILC2.80 ADAM10 also displays “sheddase” activity on CD23 and chemokines (CCL20, CCL2, CCL5, CX3CL1, CXCL8, CXCL-16).81-83 Of note, a cysteine protease (presumptively Der p 1) in an HDM extract directly induced CX3CL1 chemokine shedding in cells and confirmed in a cell-free assay using a recombinant extracellular domain of CX3CL1.83 Cleaved soluble CX3CL1 was shown to promote survival of Th2 CD4+ cells 84 and proliferation of airway smooth muscle cells leading to asthmatic airway remodeling.85**

Interestingly, Der p 1 and Der f 1 induce cytokine release in primary human keratinocytes by an unknown mechanism separate from the activation of PAR2 86 The prothrombinase activity of Der p 1 raises the possibility that, like the airways, the innate response of skin stimulated by HDM may require the canonical activation of PAR1 and PAR4. However, unlike the airways where the accepted view is that TLR4, TSLP and IL-33 have significant roles in sensitization and allergic inflammation, deficiency in TLR4 or IL-33 but not TSLP ~~is~~ **seems** tolerated in skin.10,21,87

Airway exposure of naïve mice to papain, bromelain or *Aspergillus*-associated protease promotes IL-33 production.8,88,89 Such protease-dependent IL-33 secretion is critical for the recruitment and activation of ILC2 cells.90 Serine proteases from HDM, *Alternaria* or pollen extracts can induce the release of other DAMPs than IL-33, such as uric acid and ATPs by human bronchial epithelial cells.13,91

Der p 1 and HDM extracts downregulate indoleamine 2,3-dioxygenase (IDO), a key molecule to preserve immune tolerance, in both dendritic cells and AECs.92,93 Although the underlying mechanism is unknown, it is noteworthy that ligation of TLR4 decreases IDO activity in AECs,92 suggesting that the primary signal which breaks tolerance might be the Der p 1-dependent formation of thrombin and activation of signaling via PAR1 and PAR4 with the consequent activation of TLR4 by endogenous ligands.6,75,76

The proteolytic activity of fungal Pen ch 13 down regulates CD44 expression in human bronchial epithelial cells.68 However, whether this change in expression of a receptor involved in epithelial repair resulted from the proteolytic cleavage by Pen ch 13 is unknown.

Der p 1 and Per a 10 (Cockroach) reduce the expression of CD40 on dendritic cells (DCs), an important receptor for IL-12/IFNγ production through CD40 and CD40L (expressed on T-cells) interaction pathway.63,64 However, only Der p 1 was shown to shed CD40 (sCD40 release) directly from DCs surface.63 Furthermore, DC-SIGN (CD209), a C-type lectin receptor primarily expressed on DCs and macrophages can be cleaved by Der p 1,65 down-regulating DC-SIGN-ICAM3 signalling for the differentiation of Th1 cells.66 A closely related molecule, DC-SIGNR/L-SIGN (CD299) was also known to be cleaved by Der p 1.65

**Der p 1 upregulated CD86 expression and mediated the release of pro-Th2 TARC (CCL17) and MDC (CCL22) in DCs from HDM-allergic patients through its protease activity. Purified T cells from HDM-sensitive patients stimulated by autologous active Der p 1--pulsed DCs produced large amounts of IL-4, an effect prevented by anti-CD86 antibodies. Proteolytically active Der p 1 or papain can mediate an-IgE-independent activation of mouse basophils leading to secretion of IL-4 and TSLP. Der p 1, but not papain, can induce similar effects in human basophils. The identity of the papain/Der p 1-activated sensor(s) expressed by basophils remains unknown. PARs are unlikely candidates as they cannot be functionally activated by cysteine proteases, but** Mas-related G-protein-coupled receptors (Mrgprs), innate **nociceptive sensors**,  **participate in IgE-independent basophil activation. Of note, human MRGPRX1 and mouse MRGPRC11** can be activated by Der p 1 and Der f 1 through cleavage of the N-terminal activation region, leading to IL-6 secretion.67

Der p 1 or Per a 10 selectively sheds cell surface receptors such as CD23 (FcεRII, a low-affinity IgE Fc receptor) on B cells and CD25 (IL-2 receptor) on both CD4 and CD8 T-cells.38,69-71 Soluble CD23 (sCD23) positively regulates the IgE production,72 whereas shedding of CD25 by protease allergens down-regulates ~~the~~ Th1 polarization.73 **Active Der p 1, Der f 1 or papain can directly mediate the degranulation of human eosinophils and the production of superoxide anion. Active Der p 1 can directly exert proasthmatic-like effects by its capacity to mediate MAPK-dependent rabbit airway smooth muscle responsiveness *in vitro*. The serine protease activity of fungal Asp f 13 provoked AHR by infiltrating bronchial submucosa in mice. Without prior allergic sensitization, Asp f 13, modulates in human ASM cells profound changes in cell morphology, Ca2+ mobilization and degradation of the extracellular matrix.**

**Protease-activated receptor (PAR) activation by protease allergens**

A key mechanism of the innate immune response initiated by some protease allergens involves the proteolytic activation of G-protein-coupled PARs, best known for their stimulation by the coagulation cascade enzyme, thrombin.94-96 Activation of this unique family of receptors is caused by the proteolytic unmasking of a ‘tethered’ receptor-activating ligand. The protease-revealed N-terminal sequence interacts with the extracellular receptor domain 2 to stimulate signal transduction as illustrated in Fig.4.A for PAR2 but is also the same for PAR1 and PAR4.

PARs are widely expressed in the airways by lung epithelial cells, airway smooth muscle and both tissue resident and recruited inflammatory cells, as well as by esophageal epithelium.51 The multiple signaling pathways activated following PAR engagement have been reviewed in depth previously.96-99

To date ~~only a~~few **serine protease** allergens ~~with serine protease activities~~ have been shown to target PARs directly,with PAR2 as the main example. The allergens and crude extracts with documented PAR2-regulating proteases are HDM, cockroach and mold allergens.100-102 Initially, it was reported that the major HDM allergen Der p 1 could activate PAR2;103 but subsequent studies showed that Der p 1 cleaved PAR2 at a non-activating site102 (Fig.4B). In contrast, trypsin-like Der p 3 102,104 and collagenase-like Der p 9 104 activate PAR2 in AECs and induce the release of cytokines and chemokines including GM-CSF and eotaxin. Similarly, the *D. farinae* allergen-derived enzyme, Der f 3 (80% homologous to Der p 3) induces IL-6, IL-8 and GM-CSF release from AECs through its protease activity and PAR2 activation.18 Tyr p 3 from the storage mite *Tyrophagus putrescentiae*  has serine protease-dependent effects on AECs that are prevented by both a PAR2 and a serine protease, inhibitor.15 These observations illustrate the clear activity of serine protease allergens on PAR2, although the specificity of Der f 3 to induce cytokines associated with IL-17 responses, is hard to explain based alone on PAR2-mediated activation of AECs.105,106

*Alternaria* alkaline serine protease activates PAR2 directly and induces allergic airway inflammation in mice.100 Additionally, various fungal allergen extracts, including *Alternaria* 107,108 and *Aspergillus* 109 extracts, have been shown to activate AEC, eosinophils, and induce cytokines through PAR2 but the exact proteases mediating these effects have not been identified. Fungal Pen c 13 can cleave PAR1 and PAR2 at their activation sites and desensitize AECs to increased intracellular calcium induced by PAR1 and PAR2 agonists.110 In addition, incubation of human AECs with Pen c 13 induces cytokine production that is inhibited by antibodies that prevent either PAR1 or PAR2 cleavage.

Cockroach extracts activate AECs in a PAR2-dependent fashion 111,112 and mediate PAR2-dependent sensitization of mice.113-115 Less is known regarding the cockroach allergens that can activate PAR2. Per a 10 induces PAR2-mediated effects in purified cells 116,117 and can elicit allergic sensitization in mice.116 Similarly, using a trypsin-specific activity based probe, three serine proteases from German cockroach (*Blatella germanica*) were shown to be highly homologous to Per a 10 ~~each other~~ and to activate PAR2101**. Finally, German cockroach extracts mediated the PAR2-dependent inflammatory responses of human eosinophils.**

PAR2 is not the only PAR activated by allergens, Pen c 13 can also activate PAR1.110 Among HDM allergens, Der f 3 has been shown to activate PAR1 in addition to PAR2,18 while Der p 3 can activate PAR4 and lead to PAR4-mediated activation of store-operated Ca2+ channels in mast cells.17 Interestingly, allergens indirectly activate PARs. Der p 1 can activate thrombin that then has PAR1-mediated effects on AECs;75 and Cry j 1, the major pollen allergen of *Cryptomeria japonica* (Japanese cedar), can potentially indirectly cause PAR activation by upregulating a cellular serine protease like thrombin.118

Even though we have learned more about the role of PARs in asthma and allergy from *in-vitro* and murine studies, there are limited data linking PARs and asthma or allergies in humans *in vivo*. Notwithstanding, PAR2 expression is increased in the airways of patients with asthma,119,120 and in peripheral monocytes of patients with severe asthma.121 Furthermore, in a murine model of eosinophilic esophagitis, SPINK5 or SPINK7 deficiency unleashes serine protease activity, triggering PAR2-dependent TSLP release and subsequent type 2 immunity.50,51 Given that SPINK5 deficiency underlies Netherton syndrome,122 which is marked by allergic inflammation, the impact of this deficiency may be evidence for a human link to PAR2-mediated inflammatory disease.

**The RipIL-33 pathway, IL-33 maturation and protease allergens**

It is well established that the alarmin IL-33, a member of the IL-1 cytokine family, has a critical role in the context of allergic inflammation. IL-33 secreted into the extracellular space binds ST2-expressing ILC2s, mast cells, Th2 cells, eosinophils, basophils and dendritic cells. Activation of IL-33/ST2 axis thereby contributes to the development and amplification of an allergic inflammatory response. The importance of IL-33 and its receptor in allergic responses is substantiated by genetic linkage studies. The genes *IL-33* (9p24) and *ST2/IL1RL1* (2q12) are top hits in genome-wide association studies of asthma, blood eosinophil counts in the general population, and virus-induced exacerbations in severe childhood-onset asthma.123-126 Indeed, early clinical trials with anti-IL-33 and anti-ST2 monoclonal antibodies have revealed improvements in asthma and lowering of blood eosinophil levels.127,128

IL-33 is normally localized in the nucleus of epithelial and endothelial cells 129 as an immature form of 270 amino-acids (FLIL-33) tightly bound to histone proteins associated with chromatin, through an N-terminal chromatin binding domain.130 The nuclear sequestration of IL-33 is essential for fine tuning its cytokine activity. Another control mechanism for regulating IL-33 activity is modification by proteases.

A variety of type 2 stimuli including allergens, parasites and viral component (including Toll-like receptor 3 ligands) trigger IL-33 proteolytic maturation and activation 131 and subsequent epithelial cell release in a large molecular weight complex with histones.132 Exposure of epithelial cells to a broad range of aeroallergens (including *Alternaria alternata*, HDM, *Aspergillus fumigatus*, cat dander, and cockroach extracts), but not birch pollen, Bermuda grass, peanut, whole wheat or cow milk extracts, triggers the assembly of the ripoptosome complex containing activated caspase-8, which subsequently activates caspase 3 and 7 leading to the FLIL-33 intracellular cleavage at position D175 and D178, resulting in biospecies that preserve their chromatin binding domain133 (Fig.5). Of note, exogenous allergen-associated proteolytic activity or cell damage was not required for allergen-induced intracellular IL-33 maturation. These caspase-cleaved forms of IL-33 are released before cell death and have increased ST2 bioactivity compared with IL-33FL.133 The ripoptosome-mediated cleavage, activation, and release of IL-33, referred to as RipIL-33, is a canonical pathway by which a broad range of aeroallergens (mentioned above) trigger type 2 immunity and is now considered an upstream allergen sensor.133-135 However, the capacity of individual allergens or specific components of allergen extracts to activate the RipIL-33 pathway remains to be investigated. In addition to this intracellular pathway, extracellular proteases from allergenic sources (e.g., Der p 1, papain, *Alternaria alternata*, *Aspergillus fumigatus/orizae*, ragweed, Timothy pollens), cleave full-length IL-33 between amino acids 94-110, a region referred to as the IL-33 protease sensing domain, resulting in further activation of full-length IL-33136 (Fig.5). In addition, proteases derived from inflammatory cells (e.g., elastase from neutrophils and chymase from mast cells) have potential to activate IL-33, and likely contribute to the temporal and spatial bioactivity of IL-33.

While rodent and human IL-33 can be processed into shorter mature forms by exogeneous allergen proteases (e.g. *A. alternata*), differences between the species have been reported as the murine protein can be degraded into additional inactive fragments when exposed to high concentrations of proteases136, suggesting difference in the regulation of human and mouse IL-33 by exogenous protease allergens. Interesting, a Der p 1-specific inhibitor (ADI: Allergen Delivery Inhibitor) suppresses IL-33 accumulation in the airways of sensitized rats subsequently challenged with an aerosolized HDM extract substantiating post-translational modification of IL-33 by exogeneous proteases.

**Nociceptor activation by protease allergens**

While IL-33 is a potent pro-atopy alarmin, it operates in coordination with other key signals. Recent findings have drawn attention to the cooperation between IL-33 and sensory neuron signaling. Sensory neurons originate in the dorsal root ganglia (DRG) and project throughout our body where they are enriched in barrier tissues to detect the presence of harmful stimuli. These stimuli not only include temperature and pressure, but also irritants, leading to pain or itch responses that promote protective avoidance behaviors. Trypsin and mast cell tryptase have previously been shown to activate PAR2-expressing neurons leading to neurogenic inflammation.137 Could this be a fundamental pathway guiding the detection of environmental protease allergens? In 2019, Serhan and colleagues showed that the cysteine protease activity of *D.* *farinae* extracts directly activated Transient receptor potential vanilloid 1 (TRPV1)+ dorsal root ganglia neurons in vitro.138 Extending this observation to the in vivo setting, they showed that *D.* *farinae* led to sensory neuronal release of the neuropeptide Substance P, which then activated mast cells via MRGPRB2 and led to their degranulation.138 Thus, sensory neurons detected cysteine protease allergen activity and then relayed that activation to mast cells to initiate local innate inflammatory responses. The mechanisms for the sensing of cysteine protease allergens by nociceptors remain unclear. Whereas the PAR2 activation by Der p 1 is controversial, 102,103 other cell surface receptors could be targeted, such as MRGPRX1.67 Cutaneous exposure to the cysteine protease papain promotes robust DC activation and migration in vivo, but not *in vitro*.22 This result suggested that the sensory nervous system may similarly have a role in relaying a signal of protease allergen activation to local DCs. In 2020, Perner and colleagues showed that the cysteine protease allergens papain and from HDM extract, as well as the serine protease allergens from *Alternaria* *alternata* extract were capable of activating TRPV1+ sensory neurons directly, leading to Substance P release and the sensation of itch.22 However, in addition to activating local mast cells, Perner and colleagues showed that Substance P can directly induce the migration of Th2-skewing CD301b+ DCs to the draining lymph node through their expression of MRGPRA1. DC migration was independent of mast cells, but was dependent on the presence of TRPV1+ neurons and their release of Substance P.22 Importantly, Substance P induced migration was necessary, but not sufficient for Th2 differentiation, indicating the requirement for additional signals in initiating adaptive immune responses to protease allergens (Fig.6).

**Factors Affecting the Potential Biological Significance of Protease Allergens**

**The bioactivity of proteases is regulated by intrinsic and extrinsic factors including, interaction with exogenous protease inhibitors, the prevailing redox environment, and their propensity to autolysis. Additional factors could affect the clinical relevance of protease allergens such as their environmental distribution, human exposure levels and changes in the state of these allergens when in contact with the human immune system.**

**Serine proteases are vulnerable to inhibition by endogenous antiproteases, although specific information about protease allergens and serpins in this regard is limited at present. The relevant antiproteases are themselves regulated by numerous factors, For example, ROS (which, as described earlier, can be generated by protease allergens), inhibit α1-antitrypsin {Desrochers, 1988 #156;Ossanna, 1986 #158;Vissers, 1988 #157;Weiss, 1984 #155}. Given that α1-antritrypsin is also a putative degradation target of Der p 1, this creates a potentially complex and dynamic system which might govern not only how protease activity interacts with human immunity but could determine which proteases are most influential. This remains an open area for investigation.**

**As cysteine proteases, group 1 HDM allergens have attracted speculation about whether protease activity does contribute to allergic mechanisms. This is because facile, nonrandom oxidation of the catalytic cysteine residue decreases enzyme activity. Tryptic and chymotryptic serine proteases es are also susceptible to oxidative inactivation {Prakash, 2011 #159;Suto, 2007 #160, but whether the repertoire of serine protease allergens is similarly susceptible to oxidative inactivation remains to be investigated. For cysteine proteases, such as Der p 1, important oxidations of its active site sulphydryl group are facile and reversible. However, the kinetics underlying some products, notably the formation of sulphinic or sulphonic acids, make these essentially irreversible reactions {Jacquet, 2020 #124}. Susceptibility to facile oxidation affects the preparation of any cysteine protease and this has potential implications for experimental studies. Consistent with extensive experience arising from pioneering work with papain, early studies showed that Der p 1 could be rendered catalytically active after purification. In this state, it promoted allergic sensitization, whereas inactive material did not.**

**Except in highly oxidized states, purified group 1 HDM allergens can be quickly reactivated by reducing agents, and a similar reactivation occurs in spent medium from HDM cultures {Herbert, 1990 #166;Wan, 1999 #122;Winton, 1998 #152}. In these and numerous other experimental studies described in the literature, this reactivation is performed simply to ensure that allergen preparations have proteolytic activity. However, in a drug discovery setting, such as the design of inhibitors of group 1 HDM allergens, it has been an elective procedural step to ensure uniform behaviour across a screening campaign {Newton, 2014 #133;Zhang, 2018 #118;Zhang, 2022 #176} where the absence of consistency would be detrimental to sound decision-making in chemical design. Although procedural for a specific purpose, its basis has several plausible biological equivalents in nature. These may be important determinants of protease activation *in vivo* and thus the significance of protease activity in allergy. In the human respiratory tract, airway surface liquid (ASL) contains small biothiols such as cysteine or glutathione which are known to reactivate group 1 HDM allergens *in vitro* and probably any other cysteine protease allergen{Iyer, 2009 #163;Iyer, 2009 #162;Zhang, 2016 #117;Zhang, 2018 #118;Zhang, 2018 #121}. The concentration of glutathione in ASL exceeds its levels in plasma and can be increased to millimolar levels in disease {Biswas, 2009 #161;Cantin, 1987 #178;Kelly, 1999 #182;Moss, 2000 #179;Roum, 1993 #180;Smith, 1993 #177}. Interestingly, glutathione levels in ASL are reported to be elevated in asthma as judged by measurements in bronchoalveolar lavage {Smith, 1993 #177}. Free thiols on proteins dissolved in ASL or presented on cell membranes provide further potential reductants; among these is α1-antitrypsin which is both thiol-rich and cleavable by Der p 1 {Brown, 2003 #186;Hansen, 2009 #183;Jacquet, 2020 #124;Kalsheker, 1996 #187;Thomas, 1995 #185}. Collectively, these observations provide reasons to believe that activatable cysteine protease allergens would be catalytically functional *in vivo* and they raise an interesting possibility that some cleavage targets might themselves provide the mechanism of activation as part of substrate acquisition by the enzyme’s binding pockets. Moreover, *in vitro* studies show that epithelial cells in culture activate Der p 1 or spent medium from HDM cultures to protease activity levels approaching the behaviour of pre-reduced reagents, consistent with all possibilities already outlined {Herbert, 1995 #165}. In passing, a cautionary note concerns the pitfalls of studies investigating allergen activation *in vivo*, or the difficulties in making retrospective analyses of earlier literature where pre-activated and non-activated allergens have been used in rodent models. The inherent problem is created by the high dilution of ASL by the delivered material. This is most extreme for nasal delivery where ASL is both low in volume and its reductant concentration is ~60% lower than in the lungs {Hatch, 1992 #184}. A similar concern applies to aerosol delivery to the lungs where, despite the higher concentration of biothiols, the diluting effect of aerosols contributes a significant experimental variable {Zhang, 2022 #176}. Consequently, the resulting concentration of endogenous reductants may fall below a threshold required to achieve rapid activation of the allergen. This is important when evaluating data from pioneer literature where data for activated and non-activated allergen preparations have been reported, but where the experimental purpose was not to determine the possibility of *in vivo* activation *per se*.**

**The effects of protease allergens on the allergic response are largely dependent on the concentration of their active forms from real environments. Although measurements of specific protease allergen content as Der p 1 have been reported in the literature over many years {Custovic, 2015 #167}, information about the level of their enzymatic activity is poorly characterized by the lack of specific assays of meaningful sensitivity. Such activity measurements would greatly help in the characterization of the disposition and residence time of the protease allergens in the environment, temperature, and humidity of the microenvironment. We are unaware of data which have addressed these matters systematically in a realistic setting, but it is noteworthy that Der p 1 remains activatable in HDM fecal pellets stored at room temperature for several months and remains able to cleave interepithelial tight junctions {Wan, 1999 #122}.**

**One approach to evaluate the contribution of protease activity to allergy is through the use of inhibitors. Excepting group 1 HDM allergens, this is currently restricted to generic inhibitors which lack the potency and selectivity to permit the unambiguous interrogation of even simple experimental models. A surprising feature is the extent to which the acute response to HDM extracts that can be inhibited in sensitized animals with Der p 1-specific inhibitors, suggesting that, at least in experimental models, IgE-independent events driven by group 1 allergens make substantial and decisive contributions to acute allergic responses. However, these findings should not be interpreted as indicating an absence of roles for allergens with other bioactivities, whether they be protease or not, in the complex cascade of events that link events at the airway surface to physiological, immunological and pathophysiological responses {Zhang, 2022 #176}.**

**Conclusions and perspectives**

The present review provides evidence for the prominent role of protease allergens in the initiation-regulation of the allergic response. 139,140 Proteolytic activity disturbs the integrity of the epithelial barrier and triggers a set of pleiotropic signaling effects favoring Th2 polarization. Although the protease-dependent innate immune mechanisms remain to be fully characterized, TLR4/PAR signaling pathways are activated by protease allergens from various sources to trigger epithelial inflammation in the airway, skin and likely esophagus. IL-33 plays an important role in initiating allergic inflammation in the lung where proteolytically active allergens play a critical role in IL-33 maturation, augmenting its biological activity141. However, the situation may be more complex in the skin where the role of IL-33 in the development of allergic inflammation is controversial.142 Recently, intracellular maturation of IL-33 was shown to be concomitant to exposure to protease and non-protease containing allergens, occurring via the caspase-8/ripoptosome and leading to the generation and release of bioactive mature IL-33 through a process referred to as “RipIL-33”.142 There, TRPV1+ nociceptors have been shown to sense protease allergens upstream from the cDC2-mediated activation and migration. While the understanding of underlying mechanisms has evolved significantly, it is instructive to recall that the expansive repertoire of crucial bioactivities now known to be associated with protease allergens echo aspects of the ‘Danger Model’ proposed by Matzinger143 in which danger/alarm signals were predicted to direct the development of immune responses. The pleiotropic actions of protease allergens lead to their supremacy in the hierarchy of allergenic proteins as initiators, facilitating both mono- and poly-sensitization to non-protease allergens from the same or other sources, respectively. Observational birth cohort studies provide a further perspective on the concept of an initiator allergen in identifying them as the entit(y)/(ies) responsible for the induction of the first IgE antibody response to a particular allergenic source. Der p 1 has been characterized as such by birth cohort studies, but it is clear that other potential initiators from established allergenic sources (eg HDM Der p 2 and Der p 23, pollen Phl p 1 or Bet v 1 and cat Fel d 1 allergens) lack protease activity *per se*.139,140,144 While this picture might easily arise from their association with other allergenic or non-allergenic proteases, **these allergens are independently able to trigger pro-Th2 innate immune events. In this context, an important allergenic activity consists in the propensity of allergens to transport different lipid cargo and their lipid ligands could, in turn, mediate pro-Th2 TLR2/TLR4 signaling. Interestingly, Der p 2, Bet v 1 or Fel d 1 belong to families of lipid binding proteins and Der p 2 mediates TLR4- but also TLR2-dependent proinflammatory responses. The complexity of the allergen sensing** serves as a reminder that our understanding of the innate immune programming of allergy and its interaction with genetic predispositions remains rudimentary.145-147

Despite all we have learned, our mechanistic understandings of how protease allergens induce the allergic response remains unresolved. Moreover, most of the data on protease allergens were focused on Der p 1 or proteolytically active HDM extracts, and it is presently unclear as to what extent these principles can be simply applied to other protease allergens. Adding to this uncertainty, many results have been reported using commercial or in-house allergen extracts. Producer-dependent differences in extract manufacturing can inevitably lead to variabilities in allergen composition and the preservation of crucial bioactivities, rendering data interpretation particularly challenging.148-150 Moreover, allergen extracts frequently contain allergens with lipid-binding properties and contaminating microbial compounds, both capable of generating similar allergic effects, but likely through different mechanisms clouding our ability to study any specific pathway. There is thus an urgent need for standardized allergen extract manufacturing which preserves protease activities to facilitate the comparison of data on the pro-allergic role of proteolytically active extracts, but also on the degradome of allergenic sources. Highly purified proteases from allergenic sources are needed to determine whether they can be classified as allergens (proteins eliciting IgE response) and to attribute their specific role in the allergic response unambiguously.

Several important questions about protease allergens remain unanswered and must be dealt with through multiple areas of research (Box 2 and Fig.7).

**BOX 2 Future research perspectives**

* **Standardization of allergen extracts manufacturing and protease allergen isolation to ensure comparative studies**
* **Degradome analysis of allergen extracts for the complete identification of proteases**
* **IgE binding and cross-linking assays to classify the isolated proteases as allergens**
* **Thorough characterization of protease allergens on innate immune activation**
* **Degradomics approaches for the identification of protein substrates from immune, epithelial or neuronal cells**
* **Transcriptomic analysis for the elucidation of signaling pathways mediated by protease allergens**
* **Elucidation of the structure of identified protease allergens for the design of potent inhibitors and Preclinical/clinical evaluation of anti-protease protocols to treat allergic inflammation,**
* **Effect of protease allergens on host-microbe communication**
* **Maturation of cellular protein targets by protease allergens (endogenous proteases, alarmin)**
* **Impact of protease activity on the stability of allergens in allergenic extracts.**
* **Interaction of protease and non-protease allergen signaling pathways, such as convergence in IL-33 maturation by the ripoptosome.**

The proteolytic degradation or activation of non-protease allergens co-existing with protease allergens are, to our knowledge, fully ignored. Cleavages of these could critically affect the stability, allergenicity and the antigen presentation of these non-protease allergens. Multi-OMIC approaches utilizing, in particular, single-cell transcriptomics and mass spectrometry-based proteomics would enable an extensive characterization of the signaling pathways activated by protease allergens and their protein substrate repertoire. The cleavage specificity of proteases could be determined from peptide library of FRET substrates by high-throughput screening, a method successfully used for Der p 1.151 Alongside well-characterized and commonly used epithelial cell lines, protease-treated primary cell cultures could more closely mimics the exposure of epithelium to the natural allergens. However, heterogeneity in cellular composition complicates data interpretation.152 Of note, besides IL-33 other alarmins belonging to the IL-1 family similarly contain a protease sensor domain which could be cleaved by protease **allergens, as recently evidenced for IL-1α and IL-36,.** The mechanism of allergen sensing by RipIL-33 deserves attention. The elucidation of the mechanism by which nociceptive neurons sense cysteine protease allergens directly (papain, HDM) is essential to our understanding of the neuron-immune interactions in allergic diseases. In this regard, **the** unanticipated effect of Der p 1 inhibitors **in attenuating** acute allergic bronchoconstriction **is noteworthy**.6 Neuronal cell lines or induced-pluripotent stem cell (iPSCs)-derived neurons are urgently needed to replace the primary neurons which are challenging to isolate and culture. As skin, gut or airway epithelia are continuously interacting with endosymbiotic bacteria and pathogens,153 it remains to be determined whether protease allergens, through cleavage of surface bacterial antigens, could modulate the microbiota and the virulence of pathogenic bacteria. The potentiation of infectivity of influenza or rhinovirus by HDM protease allergens 83,154 should incite further investigation of the effects of allergenic proteases on the pathogenicity of respiratory viruses including SARS-CoV-2 for which proteolytic cleavage of the COVID-19 spike protein is essential for the virus to infect angiotensin converting enzyme-2 (ACE2)-expressing lung epithelial cells.155

Structure-based design of specific inhibitors for protease allergens represents an innovative therapeutic intervention for the treatment of allergic diseases. Such an approach was adopted to design allergen delivery inhibitors (ADIs) against group 1 HDM cysteine protease allergens.6 Furthermore, epicutaneous application of inhibited papain was able to prevent Th2 inflammation in mice.156

Preclinical studies showed that pharmaceutically-developable Der p 1-specific ADI compounds prevented allergic sensitization; inhibited dendritic cell, B-lymphocyte and eosinophil recruitment to the airways; and attenuated bronchoconstriction.6,157 These compounds have the credentials for dry powder delivery to the airways and provide durable protection against HDM challenge.155 Human trials will be needed to confirm the translation of these promising animal results to clinically significant efficacy in humans.

**References**

1. Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. *Allergy*. Jul 2020;75(7):1582-1605. doi:10.1111/all.14318

2. Caraballo L, Valenta R, Puerta L, et al. The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources. *World Allergy Organ J*. May 2020;13(5):100118. doi:10.1016/j.waojou.2020.100118

3. Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. *Nat Immunol*. Mar 2008;9(3):310-8. doi:10.1038/ni1558

4. Kheradmand F, Kiss A, Xu J, Lee SH, Kolattukudy PE, Corry DB. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. *J Immunol*. Nov 15 2002;169(10):5904-11. doi:10.4049/jimmunol.169.10.5904

5. Phipps S, Lam CE, Kaiko GE, et al. Toll/IL-1 signaling is critical for house dust mite-specific helper T cell type 2 and type 17 [corrected] responses. *Am J Respir Crit Care Med*. May 15 2009;179(10):883-93. doi:10.1164/rccm.200806-974OC

6. Zhang J, Chen J, Newton GK, Perrior TR, Robinson C. Allergen Delivery Inhibitors: A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens through Structure-Based Protease Inhibitor Design. *Mol Pharmacol*. Sep 2018;94(3):1007-1030. doi:10.1124/mol.118.112730

7. Zhang J, Chen J, Zuo J, et al. Allergen Delivery Inhibitors: Characterisation of Potent and Selective Inhibitors of Der p 1 and Their Attenuation of Airway Responses to House Dust Mite Allergens. *Int J Mol Sci*. Oct 15 2018;19(10):1-34. doi:10.3390/ijms19103166

8. Kamijo S, Takeda H, Tokura T, et al. IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. *J Immunol*. May 1 2013;190(9):4489-99. doi:10.4049/jimmunol.1201212

9. Kukreja N, Sridhara S, Singh BP, Arora N. Effect of proteolytic activity of Epicoccum purpurascens major allergen, Epi p 1 in allergic inflammation. *Clin Exp Immunol*. Nov 2008;154(2):162-71. doi:10.1111/j.1365-2249.2008.03762.x

10. Shimura S, Takai T, Iida H, et al. Epicutaneous Allergic Sensitization by Cooperation between Allergen Protease Activity and Mechanical Skin Barrier Damage in Mice. *J Invest Dermatol*. Jul 2016;136(7):1408-1417. doi:10.1016/j.jid.2016.02.810

11. Sudha VT, Arora N, Gaur SN, Pasha S, Singh BP. Identification of a serine protease as a major allergen (Per a 10) of Periplaneta americana. *Allergy*. Jun 2008;63(6):768-76. doi:10.1111/j.1398-9995.2007.01602.x

12. Tripathi P, Kukreja N, Singh BP, Arora N. Serine protease activity of Cur l 1 from Curvularia lunata augments Th2 response in mice. *J Clin Immunol*. May 2009;29(3):292-302. doi:10.1007/s10875-008-9261-9

13. Schiffers C, Hristova M, Habibovic A, et al. The Transient Receptor Potential Channel Vanilloid 1 Is Critical in Innate Airway Epithelial Responses to Protease Allergens. *Am J Respir Cell Mol Biol*. Aug 2020;63(2):198-208. doi:10.1165/rcmb.2019-0170OC

14. Yu HS, Angkasekwinai P, Chang SH, Chung Y, Dong C. Protease allergens induce the expression of IL-25 via Erk and p38 MAPK pathway. *J Korean Med Sci*. Jun 2010;25(6):829-34. doi:10.3346/jkms.2010.25.6.829

15. Wang YJ, Yu SJ, Tsai JJ, Yu CH, Liao EC. Antagonism of Protease Activated Receptor-2 by GB88 Reduces Inflammation Triggered by Protease Allergen Tyr-p3. *Front Immunol*. 2021;12:557433. doi:10.3389/fimmu.2021.557433

16. Rosenstein RK, Bezbradica JS, Yu S, Medzhitov R. Signaling pathways activated by a protease allergen in basophils. *Proc Natl Acad Sci U S A*. Nov 18 2014;111(46):E4963-71. doi:10.1073/pnas.1418959111

17. Lin YP, Nelson C, Kramer H, Parekh AB. The Allergen Der p3 from House Dust Mite Stimulates Store-Operated Ca(2+) Channels and Mast Cell Migration through PAR4 Receptors. *Mol Cell*. Apr 19 2018;70(2):228-241 e5. doi:10.1016/j.molcel.2018.03.025

18. Li B, Zou Z, Meng F, et al. Dust mite-derived Der f 3 activates a pro-inflammatory program in airway epithelial cells via PAR-1 and PAR-2. *Mol Immunol*. May 2019;109:1-11. doi:10.1016/j.molimm.2019.02.018

19. Fattouh R, Pouladi MA, Alvarez D, et al. House dust mite facilitates ovalbumin-specific allergic sensitization and airway inflammation. *Am J Respir Crit Care Med*. Aug 1 2005;172(3):314-21. doi:10.1164/rccm.200502-198OC

20. Sudha VT, Arora N, Singh BP. Serine protease activity of Per a 10 augments allergen-induced airway inflammation in a mouse model. *Eur J Clin Invest*. Jun 2009;39(6):507-16. doi:10.1111/j.1365-2362.2009.02112.x

21. Togbe D, Fauconnier L, Madouri F, et al. Thymic Stromal Lymphopoietin Enhances Th2/Th22 and Reduces IL-17A in Protease-Allergen-Induced Airways Inflammation. *ISRN Allergy*. 2013;2013:971036. doi:10.1155/2013/971036

22. Perner C, Flayer CH, Zhu X, et al. Substance P Release by Sensory Neurons Triggers Dendritic Cell Migration and Initiates the Type-2 Immune Response to Allergens. *Immunity*. Nov 17 2020;53(5):1063-1077 e7. doi:10.1016/j.immuni.2020.10.001

23. Machado DC, Horton D, Harrop R, Peachell PT, Helm BA. Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE. *Eur J Immunol*. Dec 1996;26(12):2972-80. doi:10.1002/eji.1830261224

24. Seaf M, Ben-Zimra M, Mankuta D, Dayan N, Levi-Schaffer F. Papain Activates Human Mast Cells to Release Proinflammatory Mediators via its Enzymatic Activity. *J Invest Dermatol*. Jul 2016;136(7):1523-1525. doi:10.1016/j.jid.2016.03.030

25. Newton GK, Perrior TR, Jenkins K, et al. The discovery of potent, selective, and reversible inhibitors of the house dust mite peptidase allergen Der p 1: an innovative approach to the treatment of allergic asthma. *Journal of medicinal chemistry*. Nov 26 2014;57(22):9447-62. doi:10.1021/jm501102h

26. Zhang J, Chen J, Robinson C. Cellular and Molecular Events in the Airway Epithelium Defining the Interaction Between House Dust Mite Group 1 Allergens and Innate Defences. *Int J Mol Sci*. Nov 10 2018;19(11):1-32. doi:10.3390/ijms19113549

27. Tamaki FK, Pimentel AC, Dias AB, et al. Physiology of digestion and the molecular characterization of the major digestive enzymes from Periplaneta americana. *J Insect Physiol*. Nov 2014;70:22-35. doi:10.1016/j.jinsphys.2014.08.007

28. Vidal-Quist JC, Ortego F, Hernandez-Crespo P. Contribution of cysteine and serine proteases to proteolytic digestion in an allergy-eliciting house dust mite. *J Insect Physiol*. Aug-Sep 2021;133:104285. doi:10.1016/j.jinsphys.2021.104285

29. Yike I. Fungal proteases and their pathophysiological effects. *Mycopathologia*. May 2011;171(5):299-323. doi:10.1007/s11046-010-9386-2

30. Chevigne A, Barumandzadeh R, Groslambert S, et al. Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. *J Mol Biol*. Nov 16 2007;374(1):170-85. doi:10.1016/j.jmb.2007.08.025

31. Herman J, Thelen N, Smargiasso N, et al. Der p 1 is the primary activator of Der p 3, Der p 6 and Der p 9 the proteolytic allergens produced by the house dust mite Dermatophagoides pteronyssinus. *Biochim Biophys Acta*. Mar 2014;1840(3):1117-24. doi:10.1016/j.bbagen.2013.11.017

32. Ogburn RN, Randall TA, Xu Y, et al. Are dust mite allergens more abundant and/or more stable than other Dermatophagoides pteronyssinus proteins? *J Allergy Clin Immunol*. Mar 2017;139(3):1030-1032 e1. doi:10.1016/j.jaci.2016.08.016

33. Celebi Sozener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. *J Allergy Clin Immunol*. Jun 2020;145(6):1517-1528. doi:10.1016/j.jaci.2020.04.024

34. Wan H, Winton HL, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. *J Clin Invest*. Jul 1999;104(1):123-33. doi:10.1172/JCI5844

35. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. *J Appl Physiol (1985)*. Jul 1987;63(1):152-7. doi:10.1152/jappl.1987.63.1.152

36. Kelly FJ, Mudway I, Blomberg A, Frew A, Sandstrom T. Altered lung antioxidant status in patients with mild asthma. *Lancet*. Aug 7 1999;354(9177):482-3. doi:10.1016/S0140-6736(99)01812-7

37. Chen JC, Chuang JG, Su YY, Chiang BL, Lin YS, Chow LP. The protease allergen Pen c 13 induces allergic airway inflammation and changes in epithelial barrier integrity and function in a murine model. *J Biol Chem*. Jul 29 2011;286(30):26667-79. doi:10.1074/jbc.M110.193987

38. Kale SL, Agrawal K, Gaur SN, Arora N. Cockroach protease allergen induces allergic airway inflammation via epithelial cell activation. *Sci Rep*. Feb 15 2017;7:42341. doi:10.1038/srep42341

39. Henriquez OA, Den Beste K, Hoddeson EK, Parkos CA, Nusrat A, Wise SK. House dust mite allergen Der p 1 effects on sinonasal epithelial tight junctions. *Int Forum Allergy Rhinol*. Aug 2013;3(8):630-5. doi:10.1002/alr.21168

40. Boitano S, Flynn AN, Sherwood CL, et al. Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2. *Am J Physiol Lung Cell Mol Physiol*. Apr 2011;300(4):L605-14. doi:10.1152/ajplung.00359.2010

41. Nakamura T, Hirasawa Y, Takai T, et al. Reduction of skin barrier function by proteolytic activity of a recombinant house dust mite major allergen Der f 1. *J Invest Dermatol*. Dec 2006;126(12):2719-23. doi:10.1038/sj.jid.5700584

42. Ogasawara A, Yuki T, Takai T, et al. Epicutaneous challenge with protease allergen requires its protease activity to recall TH2 and TH17/TH22 responses in mice pre-sensitized via distant skin. *J Immunotoxicol*. Dec 2021;18(1):118-126. doi:10.1080/1547691X.2021.1968548

43. Iida H, Takai T, Hirasawa Y, et al. Epicutaneous administration of papain induces IgE and IgG responses in a cysteine protease activity-dependent manner. *Allergol Int*. Jun 2014;63(2):219-26. doi:10.2332/allergolint.13-OA-0621

44. Wiesner DL, Merkhofer RM, Ober C, et al. Club Cell TRPV4 Serves as a Damage Sensor Driving Lung Allergic Inflammation. *Cell Host Microbe*. Apr 8 2020;27(4):614-628 e6. doi:10.1016/j.chom.2020.02.006

45. Tulic MK, Vivinus-Nebot M, Rekima A, et al. Presence of commensal house dust mite allergen in human gastrointestinal tract: a potential contributor to intestinal barrier dysfunction. *Gut*. May 2016;65(5):757-66. doi:10.1136/gutjnl-2015-310523

46. Nesic A, Cavic M, Popovic M, et al. The Kiwifruit Allergen Act d 1 Activates NF-kappaB Signaling and Affects mRNA Expression of TJ Proteins and Innate Pro-Allergenic Cytokines. *Biomolecules*. Dec 2 2019;9(12)doi:10.3390/biom9120816

47. Cavic M, Grozdanovic MM, Bajic A, Jankovic R, Andjus PR, Gavrovic-Jankulovic M. The effect of kiwifruit (Actinidia deliciosa) cysteine protease actinidin on the occludin tight junction network in T84 intestinal epithelial cells. *Food Chem Toxicol*. Oct 2014;72:61-8. doi:10.1016/j.fct.2014.07.012

48. Grozdanovic MM, Cavic M, Nesic A, et al. Kiwifruit cysteine protease actinidin compromises the intestinal barrier by disrupting tight junctions. *Biochim Biophys Acta*. Mar 2016;1860(3):516-26. doi:10.1016/j.bbagen.2015.12.005

49. Rochman M, Azouz NP, Rothenberg ME. Epithelial origin of eosinophilic esophagitis. *J Allergy Clin Immunol*. Jul 2018;142(1):10-23. doi:10.1016/j.jaci.2018.05.008

50. Azouz NP, Ynga-Durand MA, Caldwell JM, et al. The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses. *Sci Transl Med*. Jun 6 2018;10(444)doi:10.1126/scitranslmed.aap9736

51. Azouz NP, Klingler AM, Pathre P, et al. Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis. *Sci Transl Med*. May 27 2020;12(545)doi:10.1126/scitranslmed.aaz7773

52. Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. *J Exp Med*. May 11 2009;206(5):1135-47. doi:10.1084/jem.20082242

53. Runswick S, Mitchell T, Davies P, Robinson C, Garrod DR. Pollen proteolytic enzymes degrade tight junctions. *Respirology*. Nov 2007;12(6):834-42. doi:10.1111/j.1440-1843.2007.01175.x

54. Vinhas R, Cortes L, Cardoso I, et al. Pollen proteases compromise the airway epithelial barrier through degradation of transmembrane adhesion proteins and lung bioactive peptides. *Allergy*. Aug 2011;66(8):1088-98. doi:10.1111/j.1398-9995.2011.02598.x

55. Gaspar R, de Matos MR, Cortes L, et al. Pollen Proteases Play Multiple Roles in Allergic Disorders. *Int J Mol Sci*. May 19 2020;21(10)doi:10.3390/ijms21103578

56. Bashir ME, Ward JM, Cummings M, et al. Dual function of novel pollen coat (surface) proteins: IgE-binding capacity and proteolytic activity disrupting the airway epithelial barrier. *PLoS One*. 2013;8(1):e53337. doi:10.1371/journal.pone.0053337

57. Bouley J, Groeme R, Le Mignon M, et al. Identification of the cysteine protease Amb a 11 as a novel major allergen from short ragweed. *J Allergy Clin Immunol*. Oct 2015;136(4):1055-64. doi:10.1016/j.jaci.2015.03.001

58. Ling XJ, Zhou YJ, Yang YS, et al. A new cysteine protease allergen from Ambrosia trifida pollen: proforms and mature forms. *Mol Immunol*. Jul 2022;147:170-179. doi:10.1016/j.molimm.2022.05.003

59. Hollbacher B, Schmitt AO, Hofer H, Ferreira F, Lackner P. Identification of Proteases and Protease Inhibitors in Allergenic and Non-Allergenic Pollen. *Int J Mol Sci*. Jun 5 2017;18(6)doi:10.3390/ijms18061199

60. Jacquet A, Robinson C. Proteolytic, lipidergic and polysaccharide molecular recognition shape innate responses to house dust mite allergens. *Allergy*. Jan 2020;75(1):33-53. doi:10.1111/all.13940

61. Deb R, Shakib F, Reid K, Clark H. Major house dust mite allergens Dermatophagoides pteronyssinus 1 and Dermatophagoides farinae 1 degrade and inactivate lung surfactant proteins A and D. *J Biol Chem*. Dec 21 2007;282(51):36808-19. doi:10.1074/jbc.M702336200

62. Brown A, Farmer K, MacDonald L, et al. House dust mite Der p 1 downregulates defenses of the lung by inactivating elastase inhibitors. *Am J Respir Cell Mol Biol*. Sep 2003;29(3 Pt 1):381-9. doi:10.1165/rcmb.2003-0060OC

63. Ghaemmaghami AM, Gough L, Sewell HF, Shakib F. The proteolytic activity of the major dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: allergen-induced Th2 bias determined at the dendritic cell level. *Clin Exp Allergy*. Oct 2002;32(10):1468-75. doi:10.1046/j.1365-2745.2002.01504.x

64. Goel C, Kalra N, Dwarakanath BS, Gaur SN, Arora N. Per a 10 protease activity modulates CD40 expression on dendritic cell surface by nuclear factor-kappaB pathway. *Clin Exp Immunol*. May 2015;180(2):341-51. doi:10.1111/cei.12569

65. Furmonaviciene R, Ghaemmaghami AM, Boyd SE, et al. The protease allergen Der p 1 cleaves cell surface DC-SIGN and DC-SIGNR: experimental analysis of in silico substrate identification and implications in allergic responses. *Clin Exp Allergy*. Feb 2007;37(2):231-42. doi:10.1111/j.1365-2222.2007.02651.x

66. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. *Cell*. Oct 29 2010;143(3):416-29. doi:10.1016/j.cell.2010.09.039

67. Reddy VB, Lerner EA. Activation of mas-related G-protein-coupled receptors by the house dust mite cysteine protease Der p1 provides a new mechanism linking allergy and inflammation. *J Biol Chem*. Oct 20 2017;292(42):17399-17406. doi:10.1074/jbc.M117.787887

68. Tai HY, Tam MF, Chou H, Perng DW, Shen HD. Pen ch 13 major fungal allergen decreases CD44 expression in human bronchial epithelial cells. *Int Arch Allergy Immunol*. 2010;153(4):367-71. doi:10.1159/000316347

69. Ghaemmaghami AM, Robins A, Gough L, Sewell HF, Shakib F. Human T cell subset commitment determined by the intrinsic property of antigen: the proteolytic activity of the major mite allergen Der p 1 conditions T cells to produce more IL-4 and less IFN-gamma. *Eur J Immunol*. Apr 2001;31(4):1211-6. doi:10.1002/1521-4141(200104)31:4<1211::aid-immu1211>3.0.co;2-r

70. Hewitt CR, Brown AP, Hart BJ, Pritchard DI. A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases. *J Exp Med*. Nov 1 1995;182(5):1537-44. doi:10.1084/jem.182.5.1537

71. Takai T, Kato T, Ota M, et al. Recombinant Der p 1 and Der f 1 with in vitro enzymatic activity to cleave human CD23, CD25 and alpha1-antitrypsin, and in vivo IgE-eliciting activity in mice. *Int Arch Allergy Immunol*. Jul 2005;137(3):194-200. doi:10.1159/000086331

72. Engeroff P, Vogel M. The role of CD23 in the regulation of allergic responses. *Allergy*. Jul 2021;76(7):1981-1989. doi:10.1111/all.14724

73. Shakib F, Schulz O, Sewell H. A mite subversive: cleavage of CD23 and CD25 by Der p 1 enhances allergenicity. *Immunol Today*. Jul 1998;19(7):313-6. doi:10.1016/s0167-5699(98)01284-5

74. Chen J, Zhang J, Tachie-Menson T, Shukla N, Garrod DR, Robinson C. Allergen-dependent oxidant formation requires purinoceptor activation of ADAM 10 and prothrombin. *J Allergy Clin Immunol*. Jun 2017;139(6):2023-2026 e9. doi:10.1016/j.jaci.2016.12.954

75. Zhang J, Chen J, Allen-Philbey K, et al. Innate generation of thrombin and intracellular oxidants in airway epithelium by allergen Der p 1. *J Allergy Clin Immunol*. Oct 2016;138(4):1224-1227. doi:10.1016/j.jaci.2016.05.006

76. Zhang J, Chen J, Mangat SC, Perera Baruhupolage C, Garrod DR, Robinson C. Pathways of airway oxidant formation by house dust mite allergens and viral RNA converge through myosin motors, pannexons and Toll-like receptor 4. *Immun Inflamm Dis*. Jun 2018;6(2):276-296. doi:10.1002/iid3.216

77. Millien VO, Lu W, Shaw J, et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. *Science*. Aug 16 2013;341(6147):792-6. doi:10.1126/science.1240342

78. Landers CT, Tung HY, Knight JM, et al. Selective cleavage of fibrinogen by diverse proteinases initiates innate allergic and antifungal immunity through CD11b. *J Biol Chem*. May 31 2019;294(22):8834-8847. doi:10.1074/jbc.RA118.006724

79. Burzynski LC, Humphry M, Pyrillou K, et al. The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1alpha by Thrombin. *Immunity*. Apr 16 2019;50(4):1033-1042 e6. doi:10.1016/j.immuni.2019.03.003

80. Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. *Proc Natl Acad Sci U S A*. Jun 28 2005;102(26):9182-7. doi:10.1073/pnas.0500918102

81. Reiss K, Saftig P. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. *Semin Cell Dev Biol*. Apr 2009;20(2):126-37. doi:10.1016/j.semcdb.2008.11.002

82. Weskamp G, Ford JW, Sturgill J, et al. ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. *Nat Immunol*. Dec 2006;7(12):1293-8. doi:10.1038/ni1399

83. Loxham M, Smart DE, Bedke NJ, et al. Allergenic proteases cleave the chemokine CX3CL1 directly from the surface of airway epithelium and augment the effect of rhinovirus. *Mucosal Immunol*. Mar 2018;11(2):404-414. doi:10.1038/mi.2017.63

84. Mionnet C, Buatois V, Kanda A, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. *Nat Med*. Nov 2010;16(11):1305-12. doi:10.1038/nm.2253

85. Perros F, Dorfmuller P, Souza R, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. *Eur Respir J*. May 2007;29(5):937-43. doi:10.1183/09031936.00104706

86. Kato T, Takai T, Fujimura T, et al. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. *Allergy*. Sep 2009;64(9):1366-74. doi:10.1111/j.1398-9995.2009.02023.x

87. Stremnitzer C, Manzano-Szalai K, Willensdorfer A, et al. Papain Degrades Tight Junction Proteins of Human Keratinocytes In Vitro and Sensitizes C57BL/6 Mice via the Skin Independent of its Enzymatic Activity or TLR4 Activation. *J Invest Dermatol*. Jul 2015;135(7):1790-1800. doi:10.1038/jid.2015.58

88. Hara K, Iijima K, Elias MK, et al. Airway uric acid is a sensor of inhaled protease allergens and initiates type 2 immune responses in respiratory mucosa. *J Immunol*. May 1 2014;192(9):4032-42. doi:10.4049/jimmunol.1400110

89. Hiraishi Y, Yamaguchi S, Yoshizaki T, et al. IL-33, IL-25 and TSLP contribute to development of fungal-associated protease-induced innate-type airway inflammation. *Sci Rep*. Dec 21 2018;8(1):18052. doi:10.1038/s41598-018-36440-x

90. Halim TY, Steer CA, Matha L, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. *Immunity*. Mar 20 2014;40(3):425-35. doi:10.1016/j.immuni.2014.01.011

91. Ramu S, Menzel M, Bjermer L, Andersson C, Akbarshahi H, Uller L. Allergens produce serine proteases-dependent distinct release of metabolite DAMPs in human bronchial epithelial cells. *Clin Exp Allergy*. Feb 2018;48(2):156-166. doi:10.1111/cea.13071

92. Aldajani WA, Salazar F, Sewell HF, Knox A, Ghaemmaghami AM. Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation. *Oncotarget*. Sep 6 2016;7(36):57606-57617. doi:10.18632/oncotarget.11586

93. Maneechotesuwan K, Wamanuttajinda V, Kasetsinsombat K, et al. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. *J Allergy Clin Immunol*. Jan 2009;123(1):239-48. doi:10.1016/j.jaci.2008.10.018

94. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. *J Thromb Haemost*. Aug 2005;3(8):1800-14. doi:10.1111/j.1538-7836.2005.01377.x

95. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. *Pharmacol Rev*. Jun 2002;54(2):203-17. doi:10.1124/pr.54.2.203

96. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. *Nat Rev Drug Discov*. Jan 3 2012;11(1):69-86. doi:10.1038/nrd3615

97. Ramachandran R, Altier C, Oikonomopoulou K, Hollenberg MD. Proteinases, Their Extracellular Targets, and Inflammatory Signaling. *Pharmacol Rev*. Oct 2016;68(4):1110-1142. doi:10.1124/pr.115.010991

98. Hollenberg MD, Mihara K, Polley D, et al. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. *Br J Pharmacol*. Mar 2014;171(5):1180-94. doi:10.1111/bph.12544

99. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. *Br J Pharmacol*. May 2010;160(2):191-203. doi:10.1111/j.1476-5381.2010.00705.x

100. Yee MC, Nichols HL, Polley D, et al. Protease-activated receptor-2 signaling through beta-arrestin-2 mediates Alternaria alkaline serine protease-induced airway inflammation. *Am J Physiol Lung Cell Mol Physiol*. Dec 1 2018;315(6):L1042-L1057. doi:10.1152/ajplung.00196.2018

101. Polley DJ, Mihara K, Ramachandran R, et al. Cockroach allergen serine proteinases: Isolation, sequencing and signalling via proteinase-activated receptor-2. *Clin Exp Allergy*. Jul 2017;47(7):946-960. doi:10.1111/cea.12921

102. Adam E, Hansen KK, Astudillo Fernandez O, et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. *J Biol Chem*. Mar 17 2006;281(11):6910-23. doi:10.1074/jbc.M507140200

103. Asokananthan N, Graham PT, Stewart DJ, et al. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. *J Immunol*. Oct 15 2002;169(8):4572-8. doi:10.4049/jimmunol.169.8.4572

104. Sun G, Stacey MA, Schmidt M, Mori L, Mattoli S. Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. *J Immunol*. Jul 15 2001;167(2):1014-21.

105. Kouzaki H, O'Grady SM, Lawrence CB, Kita H. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. *J Immunol*. Jul 15 2009;183(2):1427-34. doi:jimmunol.0900904 [pii]

10.4049/jimmunol.0900904

106. Kouzaki H, Tojima I, Kita H, Shimizu T. Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells. *Am J Respir Cell Mol Biol*. Nov 2013;49(5):741-50. doi:10.1165/rcmb.2012-0304OC

107. Rivas CM, Schiff HV, Moutal A, et al. Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression. *Biochem Biophys Res Commun*. Feb 5 2022;591:13-19. doi:10.1016/j.bbrc.2021.12.090

108. Rivas CM, Yee MC, Addison KJ, et al. Proteinase-activated receptor-2 antagonist C391 inhibits Alternaria-induced airway epithelial signalling and asthma indicators in acute exposure mouse models. *Br J Pharmacol*. May 2022;179(10):2208-2222. doi:10.1111/bph.15745

109. Homma T, Kato A, Bhushan B, et al. Role of Aspergillus fumigatus in Triggering Protease-Activated Receptor-2 in Airway Epithelial Cells and Skewing the Cells toward a T-helper 2 Bias. *Am J Respir Cell Mol Biol*. Jan 2016;54(1):60-70. doi:10.1165/rcmb.2015-0062OC

110. Chiu LL, Perng DW, Yu CH, Su SN, Chow LP. Mold allergen, pen C 13, induces IL-8 expression in human airway epithelial cells by activating protease-activated receptor 1 and 2. *J Immunol*. Apr 15 2007;178(8):5237-44. doi:178/8/5237 [pii]

111. Page K, Hughes VS, Odoms KK, Dunsmore KE, Hershenson MB. German cockroach proteases regulate interleukin-8 expression via nuclear factor for interleukin-6 in human bronchial epithelial cells. *Am J Respir Cell Mol Biol*. Mar 2005;32(3):225-31. doi:2004-0231OC [pii]

10.1165/rcmb.2004-0231OC

112. Page K, Strunk VS, Hershenson MB. Cockroach proteases increase IL-8 expression in human bronchial epithelial cells via activation of protease-activated receptor (PAR)-2 and extracellular-signal-regulated kinase. *J Allergy Clin Immunol*. Dec 2003;112(6):1112-8. doi:10.1016/j.jaci.2003.08.050

S0091674903022656 [pii]

113. Page K, Ledford JR, Zhou P, Dienger K, Wills-Karp M. Mucosal sensitization to German cockroach involves protease-activated receptor-2. *Respir Res*. May 24 2010;11:62. doi:10.1186/1465-9921-11-62

114. Arizmendi NG, Abel M, Mihara K, et al. Mucosal Allergic Sensitization to Cockroach Allergens Is Dependent on Proteinase Activity and Proteinase-Activated Receptor-2 Activation. *J Immunol*. Jan 26 2011;186(5):3164-3172. doi:jimmunol.0903812 [pii]

10.4049/jimmunol.0903812

115. Asaduzzaman M, Nadeem A, Arizmendi N, et al. Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation. *Clin Exp Allergy*. Dec 2015;45(12):1844-55. doi:10.1111/cea.12628

116. Agrawal K, Arora N. Serine protease allergen favours Th2 responses via PAR-2 and STAT3 activation in murine model. *Allergy*. Mar 2018;73(3):569-575. doi:10.1111/all.13315

117. Kale SL, Arora N. Per a 10 activates human derived epithelial cell line in a protease dependent manner via PAR-2. *Immunobiology*. Apr 2015;220(4):525-32. doi:10.1016/j.imbio.2014.10.018

118. Nakanishi S, Kumamoto J, Denda M. Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1. *Sci Rep*. Oct 23 2018;8(1):15610. doi:10.1038/s41598-018-33898-7

119. Knight DA, Lim S, Scaffidi AK, et al. Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. *J Allergy Clin Immunol*. Nov 2001;108(5):797-803. doi:S0091-6749(01)82736-6 [pii]

10.1067/mai.2001.119025

120. Allard B, Levardon H, Esteves P, et al. Asthmatic Bronchial Smooth Muscle Increases CCL5-Dependent Monocyte Migration in Response to Rhinovirus-Infected Epithelium. *Front Immunol*. 2019;10:2998. doi:10.3389/fimmu.2019.02998

121. Shrestha Palikhe N, Nahirney D, Laratta C, et al. Increased Protease-Activated Receptor-2 (PAR-2) Expression on CD14++CD16+ Peripheral Blood Monocytes of Patients with Severe Asthma. *PLoS One*. 2015;10(12):e0144500. doi:10.1371/journal.pone.0144500

122. Descargues P, Deraison C, Bonnart C, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. *Nat Genet*. Jan 2005;37(1):56-65. doi:10.1038/ng1493

123. Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC. Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. *J Allergy Clin Immunol*. Mar 2013;131(3):856-65. doi:10.1016/j.jaci.2012.11.028

124. Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat Genet*. Mar 2009;41(3):342-7. doi:ng.323 [pii]

10.1038/ng.323

125. Ketelaar ME, Portelli MA, Dijk FN, et al. Phenotypic and functional translation of IL33 genetics in asthma. *J Allergy Clin Immunol*. Jan 2021;147(1):144-157. doi:10.1016/j.jaci.2020.04.051

126. Aneas I, Decker DC, Howard CL, et al. Asthma-associated genetic variants induce IL33 differential expression through an enhancer-blocking regulatory region. *Nat Commun*. Oct 21 2021;12(1):6115. doi:10.1038/s41467-021-26347-z

127. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. *N Engl J Med*. Oct 28 2021;385(18):1656-1668. doi:10.1056/NEJMoa2024257

128. Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. *J Allergy Clin Immunol*. Sep 2021;148(3):790-798. doi:10.1016/j.jaci.2021.03.044

129. Dwyer GK, D'Cruz LM, Turnquist HR. Emerging Functions of IL-33 in Homeostasis and Immunity. *Annu Rev Immunol*. Apr 26 2022;40:15-43. doi:10.1146/annurev-immunol-101320-124243

130. Jiang L, Shao Y, Tian Y, Ouyang C, Wang X. Nuclear Alarmin Cytokines in Inflammation. *J Immunol Res*. 2020;2020:7206451. doi:10.1155/2020/7206451

131. Cayrol C, Girard JP. Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. *Cytokine*. May 25 2022;156:155891. doi:10.1016/j.cyto.2022.155891

132. Travers J, Rochman M, Miracle CE, et al. Chromatin regulates IL-33 release and extracellular cytokine activity. *Nat Commun*. Aug 14 2018;9(1):3244. doi:10.1038/s41467-018-05485-x

133. Brusilovsky M, Rochman M, Rochman Y, et al. Environmental allergens trigger type 2 inflammation through ripoptosome activation. *Nat Immunol*. Oct 2021;22(10):1316-1326. doi:10.1038/s41590-021-01011-2

134. Murphy RC, Altman MC. Ignition sequence start: epithelial allergen sensing and regulation of the allergic inflammatory response. *Nat Immunol*. Oct 2021;22(10):1207-1209. doi:10.1038/s41590-021-01005-0

135. Zhu X, Sokol CL. Caspase 8 sounds the alarm for allergic inflammation. *J Allergy Clin Immunol*. Apr 2022;149(4):1218-1220. doi:10.1016/j.jaci.2021.10.016

136. Cayrol C, Duval A, Schmitt P, et al. Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. *Nat Immunol*. Apr 2018;19(4):375-385. doi:10.1038/s41590-018-0067-5

137. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat Med*. Feb 2000;6(2):151-8. doi:10.1038/72247

138. Serhan N, Basso L, Sibilano R, et al. House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation. *Nat Immunol*. Nov 2019;20(11):1435-1443. doi:10.1038/s41590-019-0493-z

139. Huang X, Tsilochristou O, Perna S, et al. Evolution of the IgE and IgG repertoire to a comprehensive array of allergen molecules in the first decade of life. *Allergy*. Feb 2018;73(2):421-430. doi:10.1111/all.13269

140. Posa D, Perna S, Resch Y, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. *J Allergy Clin Immunol*. Feb 2017;139(2):541-549 e8. doi:10.1016/j.jaci.2016.08.014

141. Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. *Front Immunol*. 2019;10:364. doi:10.3389/fimmu.2019.00364

142. Laquer V, Parra V, Lacour JP, et al. IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis. *Br J Dermatol*. Apr 28 2022;doi:10.1111/bjd.21631

143. Matzinger P. Tolerance, danger, and the extended family. *Annu Rev Immunol*. 1994;12:991-1045. doi:10.1146/annurev.iy.12.040194.005015

144. Hatzler L, Panetta V, Lau S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. *J Allergy Clin Immunol*. Oct 2012;130(4):894-901 e5. doi:10.1016/j.jaci.2012.05.053

145. Chruszcz M, Chew FT, Hoffmann-Sommergruber K, et al. Allergens and their associated small molecule ligands-their dual role in sensitization. *Allergy*. Aug 2021;76(8):2367-2382. doi:10.1111/all.14861

146. Guryanova SV, Finkina EI, Melnikova DN, Bogdanov IV, Bohle B, Ovchinnikova TV. How Do Pollen Allergens Sensitize? *Front Mol Biosci*. 2022;9:900533. doi:10.3389/fmolb.2022.900533

147. Jappe U, Schwager C, Schromm AB, et al. Lipophilic Allergens, Different Modes of Allergen-Lipid Interaction and Their Impact on Asthma and Allergy. *Front Immunol*. 2019;10:122. doi:10.3389/fimmu.2019.00122

148. Jacquet A. Characterization of Innate Immune Responses to House Dust Mite Allergens: Pitfalls and Limitations. *Front Allergy*. 2021;2:662378. doi:10.3389/falgy.2021.662378

149. Post S, Nawijn MC, Hackett TL, et al. The composition of house dust mite is critical for mucosal barrier dysfunction and allergic sensitisation. *Thorax*. Jun 2012;67(6):488-95. doi:10.1136/thoraxjnl-2011-200606

150. Valenta R, Karaulov A, Niederberger V, et al. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? *J Allergy Clin Immunol Pract*. Nov - Dec 2018;6(6):1845-1855 e2. doi:10.1016/j.jaip.2018.08.032

151. Jacquet A, Campisi V, Szpakowska M, Dumez ME, Galleni M, Chevigne A. Profiling the Extended Cleavage Specificity of the House Dust Mite Protease Allergens Der p 1, Der p 3 and Der p 6 for the Prediction of New Cell Surface Protein Substrates. *Int J Mol Sci*. Jun 27 2017;18(7)doi:10.3390/ijms18071373

152. Hewitt RJ, Lloyd CM. Regulation of immune responses by the airway epithelial cell landscape. *Nat Rev Immunol*. Jun 2021;21(6):347-362. doi:10.1038/s41577-020-00477-9

153. McCoy KD, Burkhard R, Geuking MB. The microbiome and immune memory formation. *Immunol Cell Biol*. Aug 2019;97(7):625-635. doi:10.1111/imcb.12273

154. Akaike T, Maeda H, Maruo K, Sakata Y, Sato K. Potentiation of infectivity and pathogenesis of influenza A virus by a house dust mite protease. *J Infect Dis*. Oct 1994;170(4):1023-6. doi:10.1093/infdis/170.4.1023

155. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. Apr 16 2020;181(2):281-292 e6. doi:10.1016/j.cell.2020.02.058

156. Kunimine S, Takai T, Kamijo S, et al. Epicutaneous vaccination with protease inhibitor-treated papain prevents papain-induced Th2-mediated airway inflammation without inducing Th17 in mice. *Biochem Biophys Res Commun*. Mar 26 2021;546:192-199. doi:10.1016/j.bbrc.2020.12.090

157. Zhang J, Chen J, Richardson JP, et al. Targeting an Initiator Allergen Provides Durable and Expansive Protection against House Dust Mite Allergy. *ACS Pharmacol Transl Sci*. Sep 9 2022;5(9):735-751. doi:10.1021/acsptsci.2c00022

158. Dumez ME, Herman J, Campizi V, Galleni M, Jacquet A, Chevigne A. Orchestration of an uncommon maturation cascade of the house dust mite protease allergen quartet. *Front Immunol*. 2014;5:138. doi:10.3389/fimmu.2014.00138

159. Tovey ER, Chapman MD, Platts-Mills TA. Mite faeces are a major source of house dust allergens. *Nature*. Feb 12 1981;289(5798):592-3. doi:10.1038/289592a0

160. Gonzalez-Rabade N, Badillo-Corona JA, Aranda-Barradas JS, Oliver-Salvador Mdel C. Production of plant proteases in vivo and in vitro--a review. *Biotechnol Adv*. Nov-Dec 2011;29(6):983-96. doi:10.1016/j.biotechadv.2011.08.017

161. Behnsen J, Lessing F, Schindler S, et al. Secreted Aspergillus fumigatus protease Alp1 degrades human complement proteins C3, C4, and C5. *Infect Immun*. Aug 2010;78(8):3585-94. doi:10.1128/IAI.01353-09

162. Robson GD, Huang J, Wortman J, Archer DB. A preliminary analysis of the process of protein secretion and the diversity of putative secreted hydrolases encoded in Aspergillus fumigatus: insights from the genome. *Med Mycol*. May 2005;43 Suppl 1:S41-7. doi:10.1080/13693780400024305

163. Tai HY, Tam MF, Chou H, et al. Pen ch 13 allergen induces secretion of mediators and degradation of occludin protein of human lung epithelial cells. *Allergy*. Mar 2006;61(3):382-8. doi:10.1111/j.1398-9995.2005.00958.x

**EXTRA References**

**1. Desrochers PE, Weiss SJ. Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. *The Journal of clinical investigation.* 1988;81(5):1646-1650. 10.1172/JCI113500.**

**2. Ossanna PJ, Test ST, Matheson NR, Regiani S, Weiss SJ. Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interactions. *The Journal of clinical investigation.* 1986;77(6):1939-1951. 10.1172/JCI112523.**

**3. Vissers MC, George PM, Bathurst IC, Brennan SO, Winterbourn CC. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils. *The Journal of clinical investigation.* 1988;82(2):706-711. 10.1172/JCI113651.**

**4. Weiss SJ, Regiani S. Neutrophils degrade subendothelial matrices in the presence of alpha-1-proteinase inhibitor. Cooperative use of lysosomal proteinases and oxygen metabolites. *The Journal of clinical investigation.* 1984;73(5):1297-1303. 10.1172/JCI111332.**

**5. Prakash J, Kodanko JJ. Selective inactivation of serine proteases by nonheme iron complexes. *Inorg Chem.* 2011;50(9):3934-3945. 10.1021/ic102320j.**

**6. Suto D, Iuchi Y, Ikeda Y, Sato K, Ohba Y, Fujii J. Inactivation of cysteine and serine proteases by singlet oxygen. *Arch Biochem Biophys.* 2007;461(2):151-158. 10.1016/j.abb.2007.03.020.**

**7. Jacquet A, Robinson C. Proteolytic, lipidergic and polysaccharide molecular recognition shape innate responses to house dust mite allergens. *Allergy.* 2020;75(1):33-53. 10.1111/all.13940.**

**8. Zhang J, Chen J, Richardson JP, et al. Targeting an Initiator Allergen Provides Durable and Expansive Protection against House Dust Mite Allergy. *ACS Pharmacol Transl Sci.* 2022;5(9):735-751. 10.1021/acsptsci.2c00022.**

**9. Herbert CA, Holgate ST, Robinson C, Thompson PJ, Stewart GA. Effect of mite allergen on permeability of bronchial mucosa. *Lancet.* 1990;336(8723):1132. 10.1016/0140-6736(90)92611-k.**

**10. Wan H, Winton HL, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. *The Journal of clinical investigation.* 1999;104(1):123-133. 10.1172/JCI5844.**

**11. Winton HL, Wan H, Cannell MB, et al. Class specific inhibition of house dust mite proteinases which cleave cell adhesion, induce cell death and which increase the permeability of lung epithelium. *Br J Pharmacol.* 1998;124(6):1048-1059. 10.1038/sj.bjp.0701905.**

**12. Newton GK, Perrior TR, Jenkins K, et al. The discovery of potent, selective, and reversible inhibitors of the house dust mite peptidase allergen Der p 1: an innovative approach to the treatment of allergic asthma. *Journal of medicinal chemistry.* 2014;57(22):9447-9462. 10.1021/jm501102h.**

**13. Zhang J, Chen J, Mangat SC, Perera Baruhupolage C, Garrod DR, Robinson C. Pathways of airway oxidant formation by house dust mite allergens and viral RNA converge through myosin motors, pannexons and Toll-like receptor 4. *Immun Inflamm Dis.* 2018;6(2):276-296. 10.1002/iid3.216.**

**14. Biswas SK, Rahman I. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. *Mol Aspects Med.* 2009;30(1-2):60-76. 10.1016/j.mam.2008.07.001.**

**15. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. *Journal of applied physiology.* 1987;63(1):152-157. 10.1152/jappl.1987.63.1.152.**

**16. Kelly FJ, Mudway I, Blomberg A, Frew A, Sandstrom T. Altered lung antioxidant status in patients with mild asthma. *Lancet.* 1999;354(9177):482-483. 10.1016/S0140-6736(99)01812-7.**

**17. Moss M, Guidot DM, Wong-Lambertina M, Ten Hoor T, Perez RL, Brown LA. The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. *Am J Respir Crit Care Med.* 2000;161(2 Pt 1):414-419. 10.1164/ajrccm.161.2.9905002.**

**18. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. *Journal of applied physiology.* 1993;75(6):2419-2424. 10.1152/jappl.1993.75.6.2419.**

**19. Smith LJ, Houston M, Anderson J. Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. *The American review of respiratory disease.* 1993;147(6 Pt 1):1461-1464. 10.1164/ajrccm/147.6\_Pt\_1.1461.**

**20. Iyer SS, Jones DP, Brigham KL, Rojas M. Oxidation of plasma cysteine/cystine redox state in endotoxin-induced lung injury. *Am J Respir Cell Mol Biol.* 2009;40(1):90-98. 10.1165/rcmb.2007-0447OC.**

**21. Iyer SS, Ramirez AM, Ritzenthaler JD, et al. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. *Am J Physiol Lung Cell Mol Physiol.* 2009;296(1):L37-45. 10.1152/ajplung.90401.2008.**

**22. Zhang J, Chen J, Allen-Philbey K, et al. Innate generation of thrombin and intracellular oxidants in airway epithelium by allergen Der p 1. *J Allergy Clin Immunol.* 2016;138(4):1224-1227. 10.1016/j.jaci.2016.05.006.**

**23. Zhang J, Chen J, Zuo J, et al. Allergen Delivery Inhibitors: Characterisation of Potent and Selective Inhibitors of Der p 1 and Their Attenuation of Airway Responses to House Dust Mite Allergens. *Int J Mol Sci.* 2018;19(10):1-34. 10.3390/ijms19103166.**

**24. Brown A, Farmer K, MacDonald L, et al. House dust mite Der p 1 downregulates defenses of the lung by inactivating elastase inhibitors. *Am J Respir Cell Mol Biol.* 2003;29(3 Pt 1):381-389. 10.1165/rcmb.2003-0060OC.**

**25. Hansen RE, Roth D, Winther JR. Quantifying the global cellular thiol-disulfide status. *Proc Natl Acad Sci U S A.* 2009;106(2):422-427. 10.1073/pnas.0812149106.**

**26. Kalsheker NA, Deam S, Chambers L, Sreedharan S, Brocklehurst K, Lomas DA. The house dust mite allergen Der p1 catalytically inactivates alpha 1-antitrypsin by specific reactive centre loop cleavage: a mechanism that promotes airway inflammation and asthma. *Biochem Biophys Res Commun.* 1996;221(1):59-61. 10.1006/bbrc.1996.0544.**

**27. Thomas JA, Poland B, Honzatko R. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. *Arch Biochem Biophys.* 1995;319(1):1-9. 10.1006/abbi.1995.1261.**

**28. Herbert CA, King CM, Ring PC, et al. Augmentation of permeability in the bronchial epithelium by the house dust mite allergen Der p1. *Am J Respir Cell Mol Biol.* 1995;12(4):369-378. 10.1165/ajrcmb.12.4.7695916.**

**29. Hatch GE. Comparative biochemistry of the airway lining fluid. In: Parent RA, ed. *Comparative Biology of the Normal Lung.* Vol 1. Boca Raton, FL: CRC Press; 1992:617-632.**

**30. Custovic A. To what extent is allergen exposure a risk factor for the development of allergic disease? *Clin Exp Allergy.* 2015;45(1):54-62. 10.1111/cea.12450.**

**31. Zhang J, Chen J, Newton GK, Perrior TR, Robinson C. Allergen Delivery Inhibitors: A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens through Structure-Based Protease Inhibitor Design. *Mol Pharmacol.* 2018;94(3):1007-1030. 10.1124/mol.118.112730.**

**32. Jairaman A, Maguire CH, Schleimer RP, Prakriya M. Allergens stimulate store-operated calcium entry and cytokine production in airway epithelial cells. *Sci Rep.* 2016;6:32311. 10.1038/srep32311.**

**33. King C, Brennan S, Thompson PJ, Stewart GA. Dust mite proteolytic allergens induce cytokine release from cultured airway epithelium. *Journal of Immunology.* 1998;161(7):3645-3651.**

**34. Lin YP, Nelson C, Kramer H, Parekh AB. The Allergen Der p3 from House Dust Mite Stimulates Store-Operated Ca(2+) Channels and Mast Cell Migration through PAR4 Receptors. *Mol Cell.* 2018;70(2):228-241 e225. 10.1016/j.molcel.2018.03.025.**

**35. Takahashi K, Aoki T, Kohmoto S, et al. Activation of kallikrein-kinin system in human plasma with purified serine protease from Dermatophagoides farinae. *Int Arch Allergy Appl Immunol.* 1990;91(1):80-85.**

**36. Hales BJ, Martin AC, Pearce LJ, et al. Anti-bacterial IgE in the antibody responses of house dust mite allergic children convalescent from asthma exacerbation. *Clin Exp Allergy.* 2009;39(8):1170-1178. 10.1111/j.1365-2222.2009.03252.x.**

**37. Kidon MI, Chiang WC, Liew WK, et al. Mite component-specific IgE repertoire and phenotypes of allergic disease in childhood: the tropical perspective. *Pediatr Allergy Immunol.* 2011;22(2):202-210. 10.1111/j.1399-3038.2010.01094.x.**

**38. Weghofer M, Thomas WR, Kronqvist M, et al. Variability of IgE reactivity profiles among European mite allergic patients. *Eur J Clin Invest.* 2008;38(12):959-965. 10.1111/j.1365-2362.2008.02048.x.**

**39. Yasueda H, Mita H, Akiyama K, et al. Allergens from Dermatophagoides mites with chymotryptic activity. *Clin Exp Allergy.* 1993;23(5):384-390. 10.1111/j.1365-2222.1993.tb00343.x.**

**Acknowledgments**

This work was funded in part by the following grants to A.J: Thailand Science Research and Innovation (TSRI) Fund (CU\_FRB640001\_01\_30\_2, CU\_FRB65\_hea(32)\_39\_30\_20); M.E.R: NIH R01 AI045898, U19 AI070235, R01 AI057803, the Campaign Urging Research for Eosinophilic Disease (CURED), the Buckeye Foundation, and the Sunshine Charitable Foundation and its supporters, Denise and David Bunning; C.R.: Wellcome Trust (Award 087650); J.Z.: Beijing Natural Science Foundation (Grant No. 7212153), National Natural Science Foundation of China (Grant No. 82173720); C.L.S: GSK grant, NIH (R01AI151163, R21AG072204), grants from Food Allergy Science Initiative (Boston, MA), AAAAI Faculty Development Award, and Howard Goodman Fellowship from MGH; HV: Canadian Institutes of Health Research (CIHR), the Lung Association of Alberta and Northwest Territories and the CIHR/GSK Chair in Airway Inflammation. M.D.H.: funding from the Canadian Institutes of Health Research (CIHR) and the Lung Association of Alberta and Northwest Territories. C.R. and J.Z. would like to thank their colleagues who have contributed to this work over many years.

**Conflict of interest**

C.L.S is a paid consultant (expert witness) for Bayer and Merck. C.R. and J.Z. are inventors on patents granted in multiple territories concerning allergens, protease inhibitor design and composition of matter, and medical uses thereof. St George’s, University of London is beneficial owner of this patent estate. C.R. is co-founder, and holds equity in, Aldezon Ltd. M.E.R. is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nextstone One, Bristol Myers Squibb, Astra Zeneca, Ellodi Pharma, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first seven listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children’s Hospital. The remaining authors declare that they have no conflicts of interest.

**Author contributions**

All the authors contributed to and approved the final version of the manuscript.

**Legends to Figure**

**Fig.1 The identified protease allergens inducing innate immune activation are cysteine or serine proteases**

Proteases can be classified according to the location of the cleavage site in their putative substrates (A) and to the nature of their active site residues (B). With the exception of bee venom dipeptidyl peptidase allergens, all the identified protease allergens are endopeptidases (Table S1). The arrows point to the cleavage site on the protein substrate and the red circles the terminal amino acids or dipeptides released by the proteolysis. Most of cysteine and serine protease allergens share structural homologies with Der p 1 and Trypsin respectively. The insets of panel B shows the key residues of their respective active site (Cysteine-Histidine-Asparagine or Serine-Histidine-Aspartic acid for Der p 1 and trypsin respectively). Structures taken from the Protein Data Bank (PDB, <https://www.rcsb.org/>) and figure generated using Pymol.

**Fig 2. General representation of non-IgE mediated innate inflammatory pathways mediated by protease allergens on exposed epithelial and immune cells.**

Protease allergens can alter epithelial integrity through degradations of tight (TJ) or adherens junctions (AJ) which facilitates their penetration into submucosal tissues. The junction injuries of bronchiolar club cells are sensed by mechanosensor TRPV4. Epithelial damages are initiated by protease allergens (red enzyme symbol) through their capacity to alter the antiprotease network and to degrade surfactant proteins. Serine protease allergens or thrombin (peach-coloured enzyme symbol) trigger protease-activated receptor (PAR) activation. Cleavage of fibrinogen by protease allergens or by thrombin matured by protease allergens elicits TLR4 activation. Activated and/or damaged epithelium produces intracellular ROS leading to the release a large collection of proinflammatory cytokines (IL-6, GM-CSF, TSLP, IL-25), DAMP (IL-1α, IL-33, Uric acid, ATP) and chemokines (CCL2) which activate ILC2 and cDC2. IL-4 produced by activated ILC2 initiates the Th2 differentiation. The production of IL-4, IL-5, IL-13 by Th2 cells induces the production of allergen-specific IgE, the associated sensitization/degranulation of basophils (BAS)/mast cells (MC) and the recruitment of eosinophils. ILC2-derived IL-13 drives goblet cell hyperplasia. The contacts of protease allergens with immune cells, facilitated by the epithelial barrier degradation, allow the cleavage of surface receptors (CD23, CD25, CD40, DC-SIGN/DC-SIGNR) on these target cells which optimizes the Th2-biased inflammatory response.

AJ: Adherens Junction, AT: antitrypsin,, CCL2: C-C Motif Chemokine Ligand 2, cDC: conventional dendritic cell, cDC2c: type 2 conventional DC; IDO: indoleamine 2,3-dioxygenase, MD2: myeloid differentiation factor 2, PAR: protease-activated receptor, ROS: reactive oxygen species, SLPI: secretory leukocyte protease inhibitor, SP-A/D: surfactant protein –A/D, SPINK 5/7: serine protease inhibitor Kazal type 5 or 7, TJ: tight junction, TLR4: Toll-like receptor 4,, TRPV4: Transient receptor potential vanilloid-type 4 , TSLP: thymic stromal lymphopoietin.

**Fig.3 Activation of redox-dependent signaling by the prothrombinase activity of Der p 1 and its inhibition by Der p 1 class allergen delivery inhibitors.**

Thrombin generation enables the canonical activation of PAR1 and PAR4. In addition to their canonical GPCR signaling, this initiates a signaling network involving epidermal growth factor receptor (EGFR), pannexons and the TLR4-dependent intracellular generation of reactive oxidant species. This network also receives activating inputs from sensors detecting viral RNA. All these effects can be attenuated by compounds which have been designed to inhibit group 1 allergens potently and selectively. Illustratively, a favoured molecular scaffold for inhibitor design is shown. Variation of substituents at positions P1’-P4 (Schechter-Berger nomenclature) tunes the interaction with the binding pockets (S1’-S4) of the protease allergen and confers other essential developability credentials

ADAM10: activation of a disintegrin and metalloprotease 10, EGFR: epidermal growth factor receptor, MDA-5: melanoma differentiation-associated protein 5, PAR: protease-activated receptor, RIG-1: retinoic acid-inducible gene I, ROS: reactive oxygen species, TLR3: Toll-like receptor 3

**Figure 4. Activation of Protease-activated receptor 2 (PAR2) by trypsin/KLKs or trypsin-like protease allergen.**

(A) PAR2 cleavage by trypsin/KLK or serine protease allergens unmasks PAR2’s tethered ligand resulting tethered activation ligands interact with the extracellular loop 2 domain to initiate receptor signaling via the G-proteins, Gq, G12/13 and Gi . Similar effects are triggered by a synthetic tethered ligand-mimicking peptide. (B) Differential cleavage of the N-terminus of rat PAR2 by trypsin and Der p 3, which unmask the ‘canonical’ tethered receptor-activating ligand versus Der p 1, that cleaves primarily at a distinct site to ‘disarm’ the receptor for trypsin activation. The solid and dotted blue arrows indicate major and minor cleavage sites, respectively, for Der p 1.

KLK: kallikrein.

**Fig 5. IL-33 maturation by intracellular RipIL-33 pathway and by the cleavage of IL-33 protease sensor domain exposed to protease allergens or endogenous proteases.**

Allergens from different sources trigger the caspase 8–ripoptosome signaling pathway to activate and release mature IL-33 (mIL-33). This RipIL-33 intracellular mechanism is not dependent on PAR2, protease activity of allergens or epithelial damage. In contrast, allergen-induced caspase 8 maturation is required for the downstream cleavage of caspase 3/7. Active caspase 3/7 cleave the histone-bound full-length IL-33 (FLIL-33) within the IL-1-like domain. The resulting mIL-33 biospecies bound to histone is released and activate the cognate receptor ST2. Both mIL-33 forms had higher bioactivity than FLIL-33. In response to allergens, epithelial cells can release as well histone-bound FLIL-33. Environmental protease allergens from diverse sources (HDM, fungi, pollen, papain) as well as endogenous proteases released from innate effector cells during inflammation (Elastase, Cathepsin G, Granzyme B, Tryptase, chymase) can activate IL-33 maturation through cleavages of the protease sensor domain. Such mature IL-33 forms have increased ST2 binding activity compared with FLIL-33.

**Fig.6 Sensing of protease allergens by TRPV1+ nociceptors**

Cysteine and serine protease allergens from papaya, HDM, and *Alternaria alternata* are detected directly by TRPV1+ sensory neurons in the skin leading to itch and the local release of Substance P. Substance P acts directly on mast cells through their expression of MRGPRB2, leading to mast cell degranulation. Substance P also acts on cDC2 through their expression of MRGPRA1, leading to their migration to the draining lymph node where they initiate Th2 differentiation.

cDC2: type 2 conventional DC, MRGPR: Mas-related G protein-coupled receptors, TRPV1: Transient receptor potential vanilloid-type 1

**Fig 7. Multidisciplinary approaches to tackle important research questions about protease allergens**

Degradome analysis combined with IgE binding assays are needed to elucidate the protease allergen repertoire of allergenic extracts. Signaling pathways activated by protease allergens and their protein substrate repertoire can be fully elucidated by single cell transcriptomics, degradomics and using different human cell samples (epithelial, immune or neuronal cells). The effects of protease allergens on endosymbiotic or pathogenic bacteria, viruses should be investigated to measure their impact on microbiome and microbial virulence. Proteolytic degradation of the airway antiprotease network can be measured from nasal, bronchoalveolar lavage samples. Specific inhibitors can be designed based on the structure of protease allergens, paving the way for innovative therapeutic intervention . Their preclinical and clinical evaluation, alone or in combination with α1AT/SPINK replacement therapy, caspase 8 inhibitor targeting RipIL-33 pathway or PAR2 antagonist, can pave the way to more effective management of allergic diseases.

AT: antitrypsin, SPINK: serine protease inhibitor Kazal

**TABLE 1. Protease allergens identified as stimulators of innate immune pathways**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Source type** | **Name** | **Allergen source** | **Protease family** | **Physiological role** | **MEROPS classification/Uniprot/PDB** | **Ref.** |
| Arthropod | Der p 1  Der f 1 | *Dermatophagoides pteronyssinus*  *D. farinae* (HDM) | Cysteine protease (Papain-like) | Digestive function  Maturation of Der p 3, 6, 9 | C01.073/P08176/1XKG | **158,159** |
| Der p 3  Der f 3  Tyr p 3 | *D. pteronyssinus*  *D. farinae* (HDM)  *Tyrophagus putrescentiae* | Serine protease  (Trypsin-like) | Digestive function | S01.234/P39675/N.A.  S01.234/P49275/N.A.  S01.234/C6ZDB5/N.A | **28** |
| Der p 9 | *D. pteronyssinus*  (HDM) | Serine protease | Digestive function | S01.031/Q7Z163/N.A. | **104** |
| Per a 10 | *Periplaneta americana* (American cockroach) | Serine protease  (Trypsin-like) | Digestive function | S01.510/Q1M0X9/N.A. | **27** |
| Fruit | Papain | *Carica papaya* (Papaya) | Cysteine protease | Protein turn-over  plant defence response | C01.001/P00784/2CIO | **160** |
| Act d 1 | *Actinidia deliciosa* (Kiwi) | Cysteine protease | Protein turn-over  plant defence response | C01.007/P00785/2ACT | **160** |
| Ana c 2 (Bromelain) | *Ananas comosus* (Pineapple) | Cysteine protease | Protein turn-over  plant defence response | C01.028/O23791/6YCB | **160** |
| Fungi | Asp f 13  Asp fl 13  Asp o 13 | *Aspergillus fumigatus, flavus, oryzae* (Common mold) | Subtilisin-like Alkaline serine protease | Degradation of environmental proteins for metabolic growth;  Complement evasion mechanism | S08.053/P28296/N.A.  S08.053/N.A./N.A.  S08.053/P12547/N.A. | **161,162** |
| Pen ch 13  Pen c 13 | *Penicillium chrysogenum, citrinum* | Subtilisin-like Alkaline serine protease | external digestion of macromolecular nutrients | S08.025/Q9URR2/N.A.  S08.025/N.A/N.A. | **37,163** |

N.A: Not available; MEROPS: Peptidase Database (<https://www.ebi.ac.uk/merops/> ), Uniprot: Protein sequence database (<https://www.uniprot.org/> ), PDB: Protein Data Bank (<https://www.rcsb.org/> )